TY 2012 Form 990

(A) Name and Title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)
(1) JAMES A BECK........................................................................ BOD MEMBER	2.00 .......................	X
(2) WILLIAM G BEHNKE........................................................................ BOD MEMBER	2.00 .......................	X
(3) JORGE L BENITEZ........................................................................ BOD MEMBER	2.00 .......................	X
(4) PETER B BROCK........................................................................ BOD MEMBER	2.00 .......................	X
(5) A DANA CALLOW JR........................................................................ BOD MEMBER	2.00 .......................	X
(6) SCOTT A CARROLL........................................................................ BOD MEMBER	2.00 .......................	X
(7) ELIZABETH J CLARK........................................................................ BOD MEMBER	2.00 .......................	X
(8) RODMAN N MYERS........................................................................ LIFE MEMBER	2.00 .......................	X
(9) JAMES H DAVIS PHD........................................................................ VICE CHAIR	2.00 .......................	X	X
(10) TIMOTHY DURST........................................................................ CHAIR	2.00 .......................	X	X
(11) BERNARD H GARIL........................................................................ BOD MEMBER	2.00 .......................	X
(12) PAMELA JO HAYLOCK........................................................................ BOD MEMBER	2.00 .......................	X
(13) RAANAN HOROWITZ........................................................................ BOD MEMBER	2.00 .......................	X
(14) RICHARD M JEANNERET........................................................................ BOD MEMBER	2.00 .......................	X
(15) JORGE CORTES........................................................................ BOD MEMBER	2.00 .......................	X
(16) JOSEPH B KELLEY........................................................................ BOD MEMBER	2.00 .......................	X
(17) MARIE V MCDEMMOND........................................................................ BOD MEMBER	2.00 .......................	X

(A) Name and Title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)
(18) MATTHEW WINTER........................................................................ BOD MEMBER	2.00 .......................	X				0	0
(19) STEVEN T ROSENMDFACP........................................................................ BOD MEMBER	2.00 .......................	X				0	0
(20) KENNETH M SCHWARTZ........................................................................ SECRETARY/TR	2.00 .......................	X	X			0	0
(21) KATHRYN C VECELLIO........................................................................ BOD MEMBER	2.00 .......................	X				0	0
(22) LOUISE E WARNER........................................................................ BOD MEMBER	2.00 .......................	X				0	0
(23) JOHN WALTER........................................................................ PRESIDENT &	45.00 .......................		X			573,622	54,985
(24) JAMES T NANGLE........................................................................ SVP & CFO	45.00 .......................		X			236,728	46,062
(25) LOUIS DEGENNARO........................................................................ CHIEF MISSIO	45.00 .......................			X		382,058	41,269
(26) RICHARD WINNEKER........................................................................ SVP RESEARCH	45.00 .......................			X		296,242	18,732
(27) GEORGE OMIROS........................................................................ CHIEF CAMPAI	45.00 .......................			X		279,616	41,135
(28) KETING CHU........................................................................ VP RES THERA	45.00 .......................			X		273,019	17,758
(29) DAVID TIMKO........................................................................ SVP VOLUNTEE	45.00 .......................			X		252,850	40,191
(30) NANCY KLEIN........................................................................ CHIEF MKTG &	0.00 .......................				X	451,541	22,711

(A) Name and business address	(B) Description of services	(C) Compensation
MAIL AMERICA, 174 ELKTON FARM RDFORESTVA24551	FUNDRAISING SER	4,010,903
INFOCISION, 325 SPRINGSIDE DRIVEAKRONOH44333	FUNDRASING SERV	1,791,410
PARADYZ MATERA, 5 HANOVER SQUARENEW YORKNY10004	FUNDRAISING SER	1,766,306
ROBERT MICHAEL EDUCATIONAL INSTITUT, 101 LAUREL ROADVORHEESNJ08043	EDUCATIONAL SER	1,671,489
DIRECT PRINT COMMUNICATIONS, 201 EAST SANDPOINTESANTA ANACA92707	FUNDRAISING	1,382,841
2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 47

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1	Grants and other assistance to governments and organizations in the United States. See Part IV, line 21	69,323,914	69,323,914
2	Grants and other assistance to individuals in the United States. See Part IV, line 22	45,639,792	45,639,792
3	Grants and other assistance to governments, organizations, and individuals outside the United States. See Part IV, lines 15 and 16	2,762,301	2,762,301
4	Benefits paid to or for members
5	Compensation of current officers, directors, trustees, and key employees ....	917,839	678,319	110,907	128,613
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) ....
7	Other salaries and wages	68,352,738	50,515,387	8,259,440	9,577,911
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) ....	4,238,353	2,959,935	531,305	747,113
9	Other employee benefits .......	11,672,840	8,151,949	1,463,265	2,057,626
10	Payroll taxes ...........	4,852,811	3,389,053	608,331	855,427
11	Fees for services (non-employees):
a	Management ......
b	Legal .........	659,004	373,369	111,307	174,328
c	Accounting ...........	215,134	121,887	36,336	56,911
d	Lobbying ...........	637,152	360,986	107,617	168,549
e	Professional fundraising services. See Part IV, line 17	10,134,488			10,134,488
f	Investment management fees ......	223,721	126,754	37,787	59,180
g	Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O) ........	18,094,016	10,251,427	3,056,114	4,786,475
12	Advertising and promotion ....	13,394,628	6,552,320	2,306,078	4,536,230
13	Office expenses .......	27,205,388	13,221,915	4,238,769	9,744,704
14	Information technology ......	4,892,378	2,771,847	826,331	1,294,200
15	Royalties ..
16	Occupancy ...........	8,610,084	6,187,615	1,059,436	1,363,033
17	Travel ............	4,263,241	3,034,995	551,923	676,323
18	Payments of travel or entertainment expenses for any federal, state, or local public officials ......
19	Conferences, conventions, and meetings ....	4,313,049	3,605,205	314,856	392,988
20	Interest ...........
21	Payments to affiliates .......
22	Depreciation, depletion, and amortization .....	2,987,271	1,921,375	392,513	673,383
23	Insurance ..............	598,330	403,614	70,768	123,948
24	Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a	MISCELLANEOUS	2,654,051	1,948,374	313,112	392,565
b	DUES & SUBSCRIPTIONS	336,142	164,432	57,872	113,838
c
d
e	All other expenses
25	Total functional expenses. Add lines 1 through 24e	306,978,665	234,466,765	24,454,067	48,057,833
26	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here if following SOP 98-2 (ASC 958-720).	16,986,590	9,382,892		7,603,698

Part X Balance Sheet Check if Schedule O contains a response to any question in this Part X ...............
	1	Cashnon-interest-bearing .............	6,532,613	1	5,620,937
2	Savings and temporary cash investments .........	17,034,917	2	19,656,020
3	Pledges and grants receivable, net ...........	5,178,782	3	7,252,079
4	Accounts receivable, net .............	264,507	4	81,719
5	Loans and other receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of Schedule L ..................
			5
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), persons described in section 4958(c)(3)(B), and contributing employers and sponsoring organizations of section 501(c)(9) voluntary employees' beneficiary organizations (see instructions) Complete Part II of Schedule L
			6
7	Notes and loans receivable, net .............		7
8	Inventories for sale or use ..............		8
9	Prepaid expenses and deferred charges ..........	5,875,009	9	4,851,345
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	21,600,484
b	Less: accumulated depreciation .....	10b	11,006,325	6,641,060	10c	10,594,159
11	Investments—publicly traded securities ..........	138,026,930	11	112,406,398
12	Investments—other securities. See Part IV, line 11 .....	43,892,106	12	75,862,899
13	Investments—program-related. See Part IV, line 11 .....		13
14	Intangible assets ...............		14
15	Other assets. See Part IV, line 11 ...........		15
16	Total assets. Add lines 1 through 15 (must equal line 34)......	223,445,924	16	236,325,556
	17	Accounts payable and accrued expenses .........	19,660,610	17	20,652,928
18	Grants payable .................	72,815,341	18	80,460,957
19	Deferred revenue ................	16,921,194	19	34,202,238
20	Tax-exempt bond liabilities .............		20
21	Escrow or custodial account liability. Complete Part IV of Schedule D..		21
22	Loans and other payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
	persons. Complete Part II of Schedule L..........		22
23	Secured mortgages and notes payable to unrelated third parties ..		23
24	Unsecured notes and loans payable to unrelated third parties ....		24
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D....................		25
26	Total liabilities. Add lines 17 through 25.........	109,397,145	26	135,316,123
		Organizations that follow SFAS 117 (ASC 958), check here and complete lines 27 through 29, and lines 33 and 34.
27	Unrestricted net assets ..............	100,978,174	27	90,324,737
28	Temporarily restricted net assets ...........	10,221,074	28	7,775,266
29	Permanently restricted net assets ...........	2,849,531	29	2,909,430
	Organizations that do not follow SFAS 117 (ASC 958), check here and complete lines 30 through 34.
30	Capital stock or trust principal, or current funds ........		30
31	Paid-in or capital surplus, or land, building or equipment fund .....		31
32	Retained earnings, endowment, accumulated income, or other funds		32
33	Total net assets or fund balances ...........	114,048,779	33	101,009,433
34	Total liabilities and net assets/fund balances ........	223,445,924	34	236,325,556

- TIN:

SCHEDULE A
(Form 990 or 990EZ)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section
4947(a)(1) nonexempt charitable trust.

Attach to Form 990 or Form 990-EZ. right arrow

See separate instructions.

OMB No. 1545-0047

2012

Open to Public
Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC

Employer identification number

13-5644916

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 11, check only one box.)

A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E.)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in

section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An organization that normally receives: (1) more than 331/3% of its support from contributions, membership fees, and gross

receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 331/3% of

its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses

acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. See section 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box that describes the type of supporting organization and complete lines 11e through 11h.

Type I

Type II

Type III - Functionally integrated

Type III - Non-functionally integrated

By checking this box, I certify that the organization is not controlled directly or indirectly by one or more disqualified persons other than foundation managers and other than one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2).

If the organization received a written determination from the IRS that it is a Type I, Type II, or Type III supporting organization, check this box ..................................................

Since August 17, 2006, has the organization accepted any gift or contribution from any of the
following persons?

(i) A person who directly or indirectly controls, either alone or together with persons described in (ii)

Yes

and (iii) below, the governing body of the supported organization? ................

11g(i)

(ii) A family member of a person described in (i) above? ......................

11g(ii)

(iii) A 35% controlled entity of a person described in (i) or (ii) above? ................

11g(iii)

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization in col. (i) listed in your governing document?		(v) Did you notify the organization in col. (i) of your support?		(vi) Is the organization in col. (i) organized in the U.S.?		(vii) Amount of monetary support
(i) Name of supported organization	(ii) EIN	Yes	No	Yes	No	Yes	No	(vii) Amount of monetary support


Total

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990EZ.

Cat. No. 11285F

Schedule A (Form 990 or 990-EZ) 2012

Page 2

Part II

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2008	(b) 2009	(c) 2010	(d) 2011	(e) 2012	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") ....	269,156,149	238,668,944	270,731,343	283,279,625	280,246,578	1,342,082,639
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.......
3	The value of services or facilities furnished by a governmental unit to the organization without charge..
4	Total. Add lines 1 through 3	269,156,149	238,668,944	270,731,343	283,279,625	280,246,578	1,342,082,639
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)..						141,092,274
6	Public support. Subtract line 5 from line 4.						1,200,990,365

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2008	(b) 2009	(c) 2010	(d) 2011	(e) 2012	(f) Total
7	Amounts from line 4..	269,156,149	238,668,944	270,731,343	283,279,625	280,246,578	1,342,082,639
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources...	6,950,554	4,962,639	3,145,637	2,705,046	2,260,636	20,024,512
9	Net income from unrelated business activities, whether or not the business is regularly carried on..
10	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.)..	2,816,918	1,925,834	1,779,485	1,502,044	1,974,227	9,998,508
11	Total support (Add lines 7 through 10).						1,372,105,659

Gross receipts from related activities, etc. (see instructions) ..................

179,352,415

First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization, check this box and stop here........................................ right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2012 (line 6, column (f) divided by line 11, column (f)) .........

87.530 %

Public support percentage for 2011 Schedule A, Part II, line 14 ...............

91.310 %

16a

33 1/3% support test—2012. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization ....................... right arrow

33 1/3% support test—2011. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2012. If the organization did not check a box on line 13, 16a, or 16b, and line 14
is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain
in Part IV how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported
organization ..................................................... right arrow

10%-facts-and-circumstances test—2011. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line
15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here.
Explain in Part IV how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly
supported organization ................................................ right arrow

Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions ..................................................... right arrow

Schedule A (Form 990 or 990-EZ) 2012

Page 3

Part III

Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 9 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2008	(b) 2009	(c) 2010	(d) 2011	(e) 2012	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose......
3	Gross receipts from activities that are not an unrelated trade or business under section 513..
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge..
6	Total. Add lines 1 through 5.
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons...
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public support (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2008	(b) 2009	(c) 2010	(d) 2011	(e) 2012	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) ..
13	Total support. (Add lines 9, 10c, 11, and 12.)..

First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization,
check this box and stop here............................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2012 (line 8, column (f) divided by line 13, column (f)) .........

Public support percentage from 2011 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2012 (line 10c, column (f) divided by line 13, column (f)) ......

Investment income percentage from 2011 Schedule A, Part III, line 17 .............

19a

33 1/3% support tests—2012. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ........ right arrow

33 1/3% support tests—2011. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ..... right arrow

Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions ..... right arrow

Schedule A (Form 990 or 990-EZ) 2012

Page 4

Part IV

Supplemental Information. Complete this part to provide the explanations required by Part II, line 10; Part II, line 17a or 17b; and Part III, line 12. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Explanation

Schedule A (Form 990 or 990-EZ) 2012

Additional Data

Software ID:
Software Version:

- TIN:

Schedule B
(Form 990, 990-EZ,
or 990-PF)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.

OMB No. 1545-0047

2012

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC

Employer identification number

13-5644916

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.
Note. Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, $5,000 or more (in money or
property) from any one contributor. Complete Parts I and II.

Special Rules

For a section 501(c)(3) organization filing Form 990 or 990-EZ that met the 33¹/3% support test of the regulations
under sections 509(a)(1) and 170(b)(1)(A)(vi) and received from any one contributor, during the year, a contribution of the
greater of (1) $5,000 or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h, or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For a section 501(c)(7), (8), or (10) organization filing Form 990 or 990-EZ that received from any one contributor,
during the year, total contributions of more than $1,000 for use exclusively for religious, charitable,
scientific, literary, or educational purposes, or the prevention of cruelty to children or animals. Complete Parts I, II, and
III.

For a section 501(c)(7), (8), or (10) organization filing Form 990 or 990-EZ that received from any one contributor,
during the year, contributions for use exclusively for religious, charitable, etc., purposes, but these contributions did
not total to more than $1,000. If this box is checked, enter here the total contributions that were received during
the year for an exclusively religious, charitable, etc., purpose. Do not complete any of the parts unless the General Rule
applies to this organization because it received nonexclusively religious, charitable, etc., contributions of $5,000 or more
during the year ......................... Arrow Bullet

Caution. An organization that is not covered by the General Rule and/or the Special Rules does not file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2 of its Form 990; or check the box on line H of its
Form 990-EZ or on Part I, line 2 of its Form 990-PF, to certify that it does not meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).

For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.

Cat. No. 30613XSchedule B (Form 990, 990-EZ, or 990-PF) (2012)

Schedule B (Form 990, 990-EZ, or 990-PF) (2012)

Page 2

Name of organization THE LEUKEMIA & LYMPHOMA SOCIETYINC

Part I	Contributors (see instructions). Use duplicate copies of Part I if additional space is needed.
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
RESTRICTED	RESTRICTED RESTRICTED RESTRICTED RESTRICTED, RESTRICTED RESTRICTED	$RESTRICTED	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
Schedule B (Form 990, 990-EZ, or 990-PF) (2012)

Schedule B (Form 990, 990-EZ, or 990-PF) (2012)

Page 3

Name of organization THE LEUKEMIA & LYMPHOMA SOCIETYINC

Part II	Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
Schedule B (Form 990, 990-EZ, or 990-PF) (2012)

Schedule B (Form 990, 990-EZ, or 990-PF) (2012)

Page 4

Name of organization
THE LEUKEMIA & LYMPHOMA SOCIETYINC

Employer identification number

13-5644916

Part III

Exclusively religious, charitable, etc., individual contributions to section 501(c)(7), (8), or (10) organizations
that total more than $1,000 for the year. Complete columns (a) through (e) and the following line entry.
For organizations completing Part III, enter the total of exclusively religious, charitable, etc.,
contributions of $1,000 or less for the year. (Enter this information once. See instructions.) Arrow Bullet

$
Use duplicate copies of Part III if additional space is needed.

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Schedule B (Form 990, 990-EZ, or 990-PF) (2012)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE C
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under section 501(c) and section 527
SchCMd Bullet

Complete if the organization is described below. SchCMd Bullet

Attach to Form 990 or Form 990-EZ.
SchCMd Bullet

See separate instructions.

OMB No. 1545-0047

2012

Open to Public
Inspection

If the organization answered “Yes” to Form 990, Part IV, Line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then
Round Bullet

Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
Round Bullet

Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
Round Bullet

Section 527 organizations: Complete Part I-A only.
If the organization answered “Yes” to Form 990, Part IV, Line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then
Round Bullet

Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
Round Bullet

Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.
If the organization answered “Yes” to Form 990, Part IV, Line 5 (Proxy Tax) or Form 990-EZ, Part V, line 35c (Proxy Tax), then
Round Bullet

Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC

Employer identification number

13-5644916

Part I-A

Complete if the organization is exempt under section 501(c) or is a section 527 organization.

Provide a description of the organization’s direct and indirect political campaign activities in Part IV.

Political expenditures .................................... SchCMd Bullet

Volunteer hours ........................................

Part I-B

Complete if the organization is exempt under section 501(c)(3).

Enter the amount of any excise tax incurred by the organization under section 4955 ......... SchCMd Bullet

Enter the amount of any excise tax incurred by organization managers under section 4955 ...... SchCMd Bullet

If the organization incurred a section 4955 tax, did it file Form 4720 for this year? ..............

Yes No

Was a correction made? .........................................

Yes No

If "Yes," describe in Part IV.

Part I-C

Complete if the organization is exempt under section 501(c), except section 501(c)(3).

Enter the amount directly expended by the filing organization for section 527 exempt function activities SchCMd Bullet

Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ................................... SchCMd Bullet

Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b.. SchCMd Bullet

Did the filing organization file Form 1120-POL for this year? ..........................

Yes No

Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing
organization made payments. For each organization listed, enter the amount paid from the filing organization’s funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.

For Paperwork Reduction Act Notice, see the instructions for Form 990 or 990-EZ.

Cat. No. 50084S

Schedule C (Form 990 or 990-EZ) 2012

Page 2

Part II-A

Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).

A Check SchCMd Bullet

if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).
B Check SchCMd Bullet

if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)		(b) Affiliated group totals
1a	Total lobbying expenditures to influence public opinion (grass roots lobbying) ......
b	Total lobbying expenditures to influence a legislative body (direct lobbying) .......
c	Total lobbying expenditures (add lines 1a and 1b) ...................
d	Other exempt purpose expenditures ........................
e	Total exempt purpose expenditures (add lines 1c and 1d) ...............
f	Lobbying nontaxable amount. Enter the amount from the following table in both columns.
	If the amount on line 1e, column (a) or (b) is:The lobbying nontaxable amount is:
	Not over $500,00020% of the amount on line 1e.
	Over $500,000 but not over $1,000,000$100,000 plus 15% of the excess over $500,000.
	Over $1,000,000 but not over $1,500,000$175,000 plus 10% of the excess over $1,000,000.
	Over $1,500,000 but not over $17,000,000$225,000 plus 5% of the excess over $1,500,000.
	Over $17,000,000$1,000,000.

g	Grassroots nontaxable amount (enter 25% of line 1f) .................
h	Subtract line 1g from line 1a. If zero or less, enter -0-. ................
i	Subtract line 1f from line 1c. If zero or less, enter -0-. ................
j	If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year? ......................................	Yes No

4-Year Averaging Period Under Section 501(h) (Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the instructions for lines 2a through 2f on page 4.)
Lobbying Expenditures During 4-Year Averaging Period
	Calendar year (or fiscal year beginning in)	(a) 2009	(b) 2010	(c) 2011	(d) 2012	(e) Total

2a	Lobbying nontaxable amount

b	Lobbying ceiling amount (150% of line 2a, column(e))

c	Total lobbying expenditures

d	Grassroots nontaxable amount

e	Grassroots ceiling amount (150% of line 2d, column (e))

f	Grassroots lobbying expenditures

Schedule C (Form 990 or 990-EZ) 2012

Page 3

Part II-B

Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each “Yes” response to lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.

(a)

Yes

(b)

Amount

During the year, did the filing organization attempt to influence foreign, national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:

Volunteers? .........................................

Yes

Paid staff or management (include compensation in expenses reported on lines 1c through 1i)? ....

Yes

Media advertisements? ....................................

Mailings to members, legislators, or the public? .........................

Publications, or published or broadcast statements? .......................

Yes

114,447

Grants to other organizations for lobbying purposes? .......................

Direct contact with legislators, their staffs, government officials, or a legislative body? ........

Yes

538,408

Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means? ......

Yes

132,952

Other activities? ..........................

Yes

637,152

Total. Add lines 1c through 1i ...............................

1,422,959

Did the activities in line 1 cause the organization to be not described in section 501(c)(3)? .....

If "Yes," enter the amount of any tax incurred under section 4912 .................

If "Yes," enter the amount of any tax incurred by organization managers under section 4912 .....

If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year? .......

Part III-A

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

Yes

Were substantially all (90% or more) dues received nondeductible by members? ................

Did the organization make only in-house lobbying expenditures of $2,000 or less? ................

Did the organization agree to carry over lobbying and political expenditures from the prior year? ..........

Part III-B

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered “No” OR (b) Part III-A, line 3, is answered “Yes."

Dues, assessments and similar amounts from members .....................

Section 162(e) nondeductible lobbying and political expenditures (do not include amounts of political
expenses for which the section 527(f) tax was paid).

Current year .........................................

Carryover from last year ....................................

Total ............................................

Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues .

If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year? ................................

Taxable amount of lobbying and political expenditures (see instructions) ..............

Part IV

Supplemental Information

Complete this part to provide the descriptions required for Part l-A, line 1; Part l-B, line 4; Part l-C, line 5; Part II-A (affiliated group list); Part II-A, line 2; and Part ll-B, line 1. Also, complete this part for any additional information.

Identifier	Return Reference	Explanation
	SCHEDULE C, PART II-B, LINE 1	LLS IS A MEMBER OF A NUMBER OF COALITIONS INCLUDING NATIONAL COALITION FOR CANCER RESEARCH, ALLIANCE FOR A STRONGER FDA, FRIENDS OF CANCER RESEARCH, CANCER LEADERSHIP COUNCIL, PATIENT ADVOCATE FOUNDATION, AMERICA ASSOCIATION FOR CANCER RESEARCH, CHILDREN'S CAUSE FOR CANCER ADVOCACY AND THE ANTICANCER AGENT DEVELOPMENT AND VALIDATION WORKSHOP. LLS PARTNERS WITH A NUMBER OF LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA.

Schedule C (Form 990 or 990EZ) 2012

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," to Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b
SchDMd Bullet

Attach to Form 990. SchDMd Bullet

See separate instructions.

OMB No. 1545-0047

2012

Open to Public Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC

Employer identification number

13-5644916

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" to Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .........
2	Aggregate contributions to (during year) ...
3	Aggregate grants from (during year) .....
4	Aggregate value at end of year ........

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised
funds are the organization's property, subject to the organization's exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be
used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................

Yes No

Part II

Conservation Easements. Complete if the organization answered "Yes" to Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or education) Preservation of an historically important land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements .......................	2a
b	Total acreage restricted by conservation easements ..................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 8/17/06, and not on a historic structure listed in the National Register ....................	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during
the tax year SchDMd Bullet

Number of states where property subject to conservation easement is located SchDMd Bullet

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and
enforcement of the conservation easements it holds? .............................

Yes No

Staff and volunteer hours devoted to monitoring, inspecting, and enforcing conservation easements during the year
SchDMd Bullet

Amount of expenses incurred in monitoring, inspecting, and enforcing conservation easements during the year
SchDMd Bullet

Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? .......................................

Yes No

In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" to Form 990, Part IV, line 8.

If the organization elected, as permitted under SFAS 116 (ASC 958), not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under SFAS 116 (ASC 958), to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i)

Revenues included in Form 990, Part VIII, line 1 ........................ SchDMd Bullet

(ii)

Assets included in Form 990, Part X .............................. SchDMd Bullet

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under SFAS 116 (ASC 958) relating to these items:

Revenues included in Form 990, Part VIII, line 1 .......................... SchDMd Bullet

Assets included in Form 990, Part X ............................... SchDMd Bullet

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 52283D

Schedule D (Form 990) 2012

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIII.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?........

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" to Form 990,
Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No

If "Yes," explain the arrangement in Part XIII and complete the following table:


c	Beginning balance .................................	1c
d	Additions during the year ..............................	1d
e	Distributions during the year .............................	1e
f	Ending balance ...................................	1f

Did the organization include an amount on Form 990, Part X, line 21? .....................

Yes No

If “Yes,” explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ........

Part V

Endowment Funds. Complete if the organization answered "Yes" to Form 990, Part IV, line 10.

		(a)Current year	(b)Prior year	b (c)Two years back	(d)Three years back	(e)Four years back
1a	Beginning of year balance ....	6,000,186	6,059,994	5,023,902	4,481,610	5,228,375
b	Contributions ........			111,064
c	Net investment earnings, gains, and losses	482,520	48,916	938,068	563,236	730,333
d	Grants or scholarships .....	-450,000
e	Other expenditures for facilities and programs ........
f	Administrative expenses ....	-5,049	-9,992	-13,040	-20,944	-16,432
g	End of year balance ......	6,027,657	6,000,186	6,059,994	5,023,902	4,481,610

Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

Board designated or quasi-endowment SchDMd Bullet

Permanent endowment SchDMd Bullet

48.000 %

Temporarily restricted endowment SchDMd Bullet

52.000 %

The percentages in lines 2a, 2b, and 2c should equal 100%.

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) unrelated organizations ........................

3a(i)

(ii) related organizations ........................

3a(ii)

If "Yes" to 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI

Land, Buildings, and Equipment. See Form 990, Part X, line 10.

Description of property		(b)Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a	Land .................
b	Buildings ................
c	Leasehold improvements ............	859,421	380,255	479,166
d	Equipment ................	18,564,912	8,800,199	9,764,713
e	Other .................	2,176,151	1,825,871	350,280
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).).......				10,594,159

Schedule D (Form 990) 2012

Page 3

Part VII

InvestmentsOther Securities. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b)Book value	(c) Method of valuation: Cost or end-of-year market value
(1)Financial derivatives
(2)Closely-held equity interests
(3)Other (A) FUND OF HEDGE FUNDS- OPERATING	69,452,037	F
(B) LIMITED PARTNERSHIP EQUITIES-OPERATI	2,492,002	F
(C) FUND OF HEDGE FUNDS-ENDOWMENT	2,317,410	F
(D) 457B PLAN	1,357,371	F
(E) LIMITED PARTNERSHIP EQUITIES-ENDOWME	244,079	F




Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)	75,862,899

Part VIII

InvestmentsProgram Related. See Form 990, Part X, line 13.

(a) Description of investment type		(b) Book value	(c) Method of valuation: Cost or end-of-year market value









Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)

Part IX

Other Assets. See Form 990, Part X, line 15.

(a) Description				(b) Book value









Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........

Part X

Other Liabilities. See Form 990, Part X, line 25.

1.(a) Description of liability		(b) Book value
Federal income taxes









Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)
2. Fin 48 (ASC 740) Footnote. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII .....................................................

Schedule D (Form 990) 2012

Page 4

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return
1	Total revenue, gains, and other support per audited financial statements .......			1	314,316,096
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains on investments ..........	2a	3,666,259
b	Donated services and use of facilities .........	2b	7,750,188
c	Recoveries of prior year grants ...........	2c
d	Other (Describe in Part XIII.) ............	2d	13,446,219
e	Add lines 2a through 2d .....................			2e	24,862,666
3	Subtract line 2e from line 1.....................			3	289,453,430
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a	223,721
b	Other (Describe in Part XIII.) ...........	4b	681,316
c	Add lines 4a and 4b.......................			4c	905,037
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ......			5	290,358,467

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return
1	Total expenses and losses per audited financial statements ...........			1	327,691,856
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities ..........	2a	7,750,188
b	Prior year adjustments ..............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIII.) ............	2d	13,186,724
e	Add lines 2a through 2d......................			2e	20,936,912
3	Subtract line 2e from line 1.....................			3	306,754,944
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a	223,721
b	Other (Describe in Part XIII.) ............	4b
c	Add lines 4a and 4b.......................			4c	223,721
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ......			5	306,978,665

Part XIII

Supplemental Information

Complete this part to provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b;
Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

Identifier	Return Reference	Explanation
COLLECTIONS AND RELATION TO EXEMPT PURPOSE	SCHEDULE D, PAGE 2, PART III, LINE 4	THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS.
INTENDED USES FOR ENDOWMENT FUNDS	SCHEDULE D, PAGE 2, PART V, LINE 4	LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS.
LIABILITY UNDER FIN 48 FOOTNOTE	SCHEDULE D, PAGE 3, PART X	LLS RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENE CODE SECTION 511. LLS DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2013 AND 2012.
REVENUE AMOUNTS INCLUDED IN FINANCIALS - OTHER	SCHEDULE D, PAGE 4, PART XI, LINE 2D	LLS CANADA REVENUE 13,446,524 ROUNDING -305
REVENUE AMOUNTS INCLUDED ON RETURN - OTHER	SCHEDULE D, PAGE 4, PART XI, LINE 4B	LSRP CONTRIBUTION 681,316
EXPENSE AMOUNTS INCLUDED IN FINANCIALS - OTHER	SCHEDULE D, PAGE 4, PART XII, LINE 2D	LLS CANADA EXPENSES 13,101,520 FOREIGN CURRENCY TRANSALATION ADJUSTMENT 83,698 ROUNDING 1,506
SUPPLEMENTAL FINANCIAL INFORMATION	SCHEDULE D, PAGE 4, PART XIII	LLS MAINTAINS A SMALL PHOTOGRAPH COLLECTION FOR PUBLIC EXHIBITION WHICH HAS AN ESTIMATED VALUE OF BETWEEN 20,000 AND 50,000. AS THIS REPRESENTS A RELATIVELY SMALL PERCENTAGE OF LLS'S ASSETS, IT IS NOT SEPARATELY DISCLOSED IN THE FINANCIAL STATEMENTS OR FOOTNOTES.

Schedule D (Form 990) 2012

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE F(Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" to Form 990,Part IV, line 14b, 15, or 16. Right pointing arrow large image

Attach to Form 990. Right pointing arrow large image

See separate instructions.

OMB No. 1545-0047

2012

Open to Public Inspection

Name of the organization
THE LEUKEMIA & LYMPHOMA SOCIETYINC

Employer identification number

13-5644916

Part I

General Information on Activities Outside the United States. Complete if the organization answered “Yes” to Form 990, Part IV, line 14b.

For grantmakers. Does the organization maintain records to substantiate the amount of the grants or

assistance, the grantees’ eligibility for the grants or assistance, and the selection criteria used to award

the grants or assistance? ...................................

Yes

For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of grant funds outside
the United States.

Activites per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region		(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in region	(d) Activities conducted in region (by type) (e.g., fundraising, program services, investments, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in region	(f) Total expenditures for and investments in region
	EAST ASIA	2	2	RESEARCH FUNDING	RESEARCH GRANTS	436,347
	EUROPE	6	7	RESEARCH FUNDING	RESEARCH GRANTS	762,288
	NORTH AMERICA	7	12	RESEARCH FUNDING	RESEARCH GRANTS	1,563,666
	CENTRAL AMERICA & CARIBBEAN			INVESTMENTS	INVESTMENTS













3a	Sub-total .....	15	21			23,700,532
b	Total from continuation sheets to Part I ...
c	Totals (add lines 3a and 3b)	15	21			23,700,532

For Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2012

Schedule F (Form 990) 2012

Page 2

Part II

Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered “Yes” to Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.

(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(i) Method of valuation (book, FMV, appraisal, other)
EAST ASIA & PACIFIC	RESEARCH GRANT	50,000	CHECK	ACCRUAL
EAST ASIA & PACIFIC	RESEARCH GRANT	100,000	CHECK	ACCRUAL
EAST ASIA & PACIFIC	RESEARCH GRANT	190,657	CHECK	ACCRUAL
EAST ASIA & PACIFIC	THERAPY ACCELERATION	95,690	CHECK	ACCRUAL
EUROPE	RESEARCH GRANT	110,000	CHECK	ACCRUAL
EUROPE	RESEARCH GRANT	65,000	CHECK	ACCRUAL
EUROPE	RESEARCH GRANT	50,000	CHECK	ACCRUAL
EUROPE	RESEARCH GRANT	100,000	CHECK	ACCRUAL
EUROPE	THERAPY ACCELERATION	331,503	CHECK	FMV
EUROPE	THERAPY ACCELERATION	82,300	CHECK	FMV
EUROPE	THERAPY ACCELERATION	23,485	CHECK	FMV
NORTH AMERICA	RESEARCH GRANT	200,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	50,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	55,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	505,594	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	100,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	55,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	241,290	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	55,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	100,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	100,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	100,000	CHECK	ACCRUAL
EAST ASIA & PACIFIC	RESEARCH GRANT	50,000	CHECK	ACCRUAL
EAST ASIA & PACIFIC	RESEARCH GRANT	100,000	CHECK	ACCRUAL
EAST ASIA & PACIFIC	RESEARCH GRANT	190,657	CHECK	ACCRUAL
EAST ASIA & PACIFIC	THERAPY ACCELERATION	95,690	CHECK	ACCRUAL
EUROPE	RESEARCH GRANT	110,000	CHECK	ACCRUAL
EUROPE	RESEARCH GRANT	65,000	CHECK	ACCRUAL
EUROPE	RESEARCH GRANT	50,000	CHECK	ACCRUAL
EUROPE	RESEARCH GRANT	100,000	CHECK	ACCRUAL
EUROPE	THERAPY ACCELERATION	331,503	CHECK	FMV
EUROPE	THERAPY ACCELERATION	82,300	CHECK	FMV
EUROPE	THERAPY ACCELERATION	23,485	CHECK	FMV
NORTH AMERICA	RESEARCH GRANT	200,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	50,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	55,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	505,594	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	100,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	55,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	241,290	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	55,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	100,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	100,000	CHECK	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	100,000	CHECK	ACCRUAL

Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .... MediumBullet

Enter total number of other organizations or entities ....................... MediumBullet

Schedule F (Form 990) 2012

Schedule F (Form 990) 2012Page 3

Part III

Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance		(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of non-cash assistance	(g) Description of non-cash assistance	(h) Method of valuation (book, FMV, appraisal, other)

Schedule F (Form 990) 2012

Page 4

Part IV

Foreign Forms

Schedule F (Form 990) 2012

Page 5

Part V

Supplemental Information
Complete this part to provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information (see instructions).

Identifier	ReturnReference	Explanation
PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS OUTSIDE THE UNITED STATES	SCHEDULE F, PAGE 1, PART I, LINE 2	FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS,EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT.
ACTIVITIES PER REGION	SCHEDULE F, PAGE 1, PART I, LINE 3	EAST ASIA 436,347 0 EUROPE 762,288 0 NORTH AMERICA 1,563,666 0 CENTRAL AMERICA & CARIBBEAN 0 20,938,231

Schedule F (Form 990) 2012

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE G (Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding
Fundraising or Gaming Activities

Complete if the organization answered "Yes" to Form 990, Part IV, lines 17, 18, or 19, or if the organization entered more than $15,000 on Form 990-EZ, line 6a. Form 990-EZ filers are not required to complete this part. right arrow

Attach to Form 990 or Form 990-EZ. right arrow

See separate instructions.

OMB No. 1545-0047

2012

Open to Public Inspection

Name of the organization
THE LEUKEMIA & LYMPHOMA SOCIETYINC

Employer identification number

13-5644916

Part I

Fundraising Activities. Complete if the organization answered "Yes" to Form 990, Part IV, line 17.

Indicate whether the organization raised funds through any of the following activities. Check all that apply.

a	Mail solicitations	e	Solicitation of non-government grants
b	Internet and email solicitations	f	Solicitation of government grants
c	Phone solicitations	g	Special fundraising events
d	In-person solicitations

Did the organization have a written or oral agreement with any individual (including officers, directors, trustees

or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services?

Yes

If “Yes,” list the ten highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is
to be compensated at least $5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)		(ii) Activity	(iii) Did fundraiser have custody or control of contributions?		(v) Amount paid to (or retained by) fundraiser listed in col. (i)	(vi) Amount paid to (or retained by) organization
			Yes	No
	MAIL AMERICA COMMUNICATIONS INC 174 ELKTON FARM ROAD FOREST, VA24551	DIRECT MAI		No	4,010,903	-4,010,903
	INFOCISION 325 SPRINSIDE DRIVE AKRON, OH44333	TELEMARKET		No	1,791,410	-1,791,410
	PARADYZ MATERA 5 HANOVER SQUARE 6TH FLOOR NEW YORK, NY10004	DIRECT MAI		No	1,766,306	-1,766,306
	DIRECT PRINT COMMUNICATIONS 201 EAST SANDPOINTE SUITE 400 SANTA ANA, CA92707	DIRECT MAI		No	1,382,841	-1,382,841
	THOMPSON HABIB & DENISON 80 HAYDEN AVENUE SUITE 300 LEXINGTON, MA02421	DIRECT MAI		No	670,953	-670,953
	DONOR CARE CENTER INC 4345 STRAUSSSER ST NW NOTH CANTON, OH44720	TELEMARKET		No	400,252	-400,252
	BLACKBAUD 1800 DIAGONAL ROAD SUITE 400 ALEXANDRIA, VA22314	DIRECT MAI		No	111,823	-111,823



Total .................					10,134,488	-10,134,488

List all states in which the organization is registered or licensed to solicit funds or has been notified it is exempt from registration or licensing.

All States

For Paperwork Reduction Act Notice, see the Instructions for Form 990or 990-EZ.

Cat. No. 50083H

Schedule G (Form 990 or 990-EZ) 2012

Page 2

Part II

Fundraising Events. Complete if the organization answered "Yes" to Form 990, Part IV, line 18, or reported more than $15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than $5,000.

		(a) Event #1 NIKE WOMEN HALF (event type)	(b) Event #2 NIKE WOMENS MAR (event type)	(c) Other events 1,050 (total number)	(d) Total events (add col. (a) through col. (c))
1	Gross receipts . . .	6,347,050	9,777,032	178,435,083	194,559,165
2	Less: Contributions . .	5,108,549	6,741,163	149,412,185	161,261,897
3	Gross income (line 1 minus line 2) . . .	1,238,501	3,035,869	29,154,898	33,429,268
4	Cash prizes . . .
5	Noncash prizes . .
6	Rent/facility costs . .
7	Food and beverages .
8	Entertainment . . .
9	Other direct expenses .	1,238,501	3,035,869	29,154,898	33,429,268
10	Direct expense summary. Add lines 4 through 9 in column (d) ...........				33,429,268
11	Net income summary. Combine line 3, column (d), and line 10. ..........

Part III

Gaming. Complete if the organization answered "Yes" to Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.

(a) Bingo

(b) Pull tabs/Instant
bingo/progressive bingo

(c) Other gaming

(d) Total gaming (add col.(a) through col.(c))

Gross revenue . . . .

778,030

Cash prizes . . . .

13,067

Non-cash prizes . . .

263,649

Rent/facility costs . . .

25,239

Other direct expenses . .

19,162

Volunteer labor . . .

	Yes
	No

	Yes
	No

	Yes9.000 %
	No

Direct expense summary. Add lines 2 through 5 in column (d) ........... right arrow

321,117

Net gaming income summary. Combine lines 1 and 7 in column (d) .......... right arrow

456,913

Enter the state(s) in which the organization operates gaming activities:

Is the organization licensed to operate gaming activities in each of these states? ............

YesNo

If "No," explain:

10a

Were any of the organization's gaming licenses revoked, suspended or terminated during the tax year? .....

YesNo

If "Yes," explain:

Schedule G (Form 990 or 990-EZ) 2012

Page 3

Does the organization operate gaming activities with nonmembers? .................

YesNo

Is the organization a grantor, beneficiary or trustee of a trust or a member of a partnership or other entity

formed to administer charitable gaming? ..........................

YesNo

Indicate the percentage of gaming activity operated in:

The organization's facility ......................

13a

1.000 %

An outside facility ........................

13b

99.000 %

Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name

ROSEMARIE LOFFREDO

Address

1311 MAMARONECK AVENUE
WHITE PLAINS,NY10605

15a

Does the organization have a contract with a third party from whom the organization receives gaming

revenue? ......................................

YesNo

If "Yes," enter the amount of gaming revenue received by the organization right arrow

$ and the

amount of gaming revenue retained by the third party right arrow

$ .

If "Yes," enter name and address of the third party:

Name

Address

Gaming manager information:

Name

SEE SCHEDULE G PART IV

Gaming manager compensation right arrow

Description of services provided right arrow

Director/officer Employee Independent contractor

Mandatory distributions:

Is the organization required under state law to make charitable distributions from the gaming proceeds to

retain the state gaming license? ............................

YesNo

Enter the amount of distributions required under state law distributed to other exempt organizations or spent

in the organization's own exempt activities during the tax year right arrow

Part IV

Supplemental Information. Complete this part to provide the explanations required by Part I, line 2b, columns (iii) and (v), and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also complete this part to provide any additional information (see instructions).

Identifier	Return Reference	Explanation
		SCHEDULE G PART I LINE 2B LLS USED INFOCISON MAIL AMERICA COMMUNICATIONS DONOR CARE CENTER INC AND THOMPSON HABIB DENISON FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS THESE PROGRAMS GENERATED GROSS RECEIPTS OF 21722519 DURING FISCAL YEAR 2013 LLS USED DIRECT PRINT COMMUNICATIONS PARADYZ MATERA AND BLACKBAUD FOR ALL OF ITS OTHER FUNDRAISING EVENTS DURING FISCAL YEAR 2013 SCHEDULE G PART III LINE 9STATES WITH GAMING OPERATIONS ARIZONA CALIFORNIA CONNECTICUT DISTRICT OF COLUMBIA IOWA KANSAS LOUISIANA MARYLAND MICHIGAN MINNESOTA MISSISSIPPI NEW YORK NORTH CAROLINAOHIO OREGONPENNSYLVANIA RHODE ISLAND TEXAS WISCONSIN SCHEDULE G PART III LINE 16 THE LEUKEMIA LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFF

Schedule G (Form 990 or 990-EZ) 2012

Additional Data

Software ID:
Software Version:

- TIN:

Schedule I
(Form 990)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations,
Governments and Individuals in the United States

Complete if the organization answered "Yes," to Form 990, Part IV, line 21 or 22.
lBullet

Attach to Form 990

OMB No. 1545-0047

2012

Open to Public
Inspection

Name of the organization
THE LEUKEMIA & LYMPHOMA SOCIETYINC

Employer identification number
13-5644916

Part I

General Information on Grants and Assistance

Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ....................................

Yes No

Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II

Grants and Other Assistance to Governments and Organizations in the United States. Complete if the organization answered "Yes" to
Form 990, Part IV, line 21, for any recipient that received more than $5,000. Part II can be duplicated if additional space is needed.

(a) Name and address of organization or government	(b) EIN	(c) IRC Code section if applicable	(d) Amount of cash grant	(f) Method of valuation (book, FMV, appraisal, other)	(h) Purpose of grant or assistance
(1) ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX,NY10461	13-1624225	3	200,000	ACCRUAL	RESEARCH GRANT
(2) ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX,NY10461	13-1624225	3	110,000	ACCRUAL	RESEARCH GRANT
(3) ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX,NY10461	13-1624225	3	200,000	ACCRUAL	RESEARCH GRANT
(4) BAYLOR COLLEGE OF MEDICINE 1 BAYLOR PLAZA HOUSTON,TX77030	74-1613878	3	55,000	ACCRUAL	RESEARCH GRANT
(5) BAYLOR COLLEGE OF MEDICINE 1 BAYLOR PLAZA HOUSTON,TX77002	74-1613878	3	200,000	ACCRUAL	RESEARCH GRANT
(6) BECKMAN RESEARCH INSTITUTE OF THE C 1500 DUARTE ROAD DUARTE,CA91010	95-3432210	3	200,000	ACCRUAL	RESEARCH GRANT
(7) BECKMAN RESEARCH INSTITUTE OF THE C 1500 DUARTE ROAD DUARTE,CA91010	95-3432210	3	200,000	ACCRUAL	RESEARCH GRANT
(8) BECKMAN RESEARCH INSTITUTE OF THE C 1500 DUARTE ROAD DUARTE,CA91010	95-3432210	3	200,000	ACCRUAL	RESEARCH GRANT
(9) BECKMAN RESEARCH INSTITUTE OF THE C 1500 DUARTE ROAD DUARTE,CA91010	95-3432210	3	200,000	ACCRUAL	RESEARCH GRANT
(10) BETH ISRAEL DEACONESS MEDICAL CENTE 330 BROOKLINE AVE BOSTON,MA02108	04-2103881	3	200,000	ACCRUAL	RESEARCH GRANT
(11) BETH ISRAEL DEACONESS MEDICAL CENTE 330 BROOKLINE AVE BOSTON,MA02108	04-2103881	3	65,000	ACCRUAL	RESEARCH GRANT
(12) BETH ISRAEL DEACONESS MEDICAL CENTE 330 BROOKLINE AVE BOSTON,MA02108	04-2103881	3	110,000	ACCRUAL	RESEARCH GRANT
(13) BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS ST BOSTON,MA02115	04-2312909	3	1,250,000	ACCRUAL	RESEARCH GRANT
(14) BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS ST BOSTON,MA02115	04-2312909	3	110,000	ACCRUAL	RESEARCH GRANT
(15) BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS ST BOSTON,MA02115	04-2312909	3	100,000	ACCRUAL	RESEARCH GRANT
(16) BRIGHAM AND WOMEN'S HOSPITAL INC 101 HUNTINGTON AVE SUITE 300 BOSTON,MA02115	04-2312909	3	110,000	ACCRUAL	RESEARCH GRANT
(17) BRIGHAM AND WOMEN'S HOSPITAL INC 101 HUNTINGTON AVE SUITE 300 BOSTON,MA02115	04-2312909	3	65,000	ACCRUAL	RESEARCH GRANT
(18) CALIFORNIA INSTITUTE OF TECHNOLOGY 1200 EAST CA BLVD PASADENA,CA91125	95-1643307	3	55,000	ACCRUAL	RESEARCH GRANT
(19) CASE WESTERN RESERVE UNIVERSITY - S 10900 EUCLID AVENUE CLEVELAND,OH44106	34-1018992	3	200,000	ACCRUAL	RESEARCH GRANT
(20) CHILDRENS HOSPITAL CORPORATION 300 LONGWOOD AV BOSTON,MA02108	04-2774441	3	55,000	ACCRUAL	RESEARCH GRANT
(21) CHILDRENS HOSPITAL CORPORATION 300 LONGWOOD AV BOSTON,MA02108	04-2774441	3	55,000	ACCRUAL	RESEARCH GRANT
(22) CHILDRENS HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI,OH45229	31-0833936	3	200,000	ACCRUAL	RESEARCH GRANT
(23) CHILDRENS HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI,OH45229	31-0833936	3	110,000	ACCRUAL	RESEARCH GRANT
(24) CHILDRENS HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI,OH45229	31-0833936	3	200,000	ACCRUAL	RESEARCH GRANT
(25) CHILDRENS HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI,OH45229	31-0833936	3	200,000	ACCRUAL	RESEARCH GRANT
(26) CHILDREN'S HOSPITAL LOS ANGELES 4650 SUNSET BLVD LOS ANGELES,CA90001	95-1690977	3	200,000	ACCRUAL	RESEARCH GRANT
(27) CHILDREN'S HOSPITAL OF BOSTON 300 LONGWOOD AVENUE BOSTON,MA02108	04-2774441	3	200,000	ACCRUAL	RESEARCH GRANT
(28) CHILDREN'S HOSPITAL OF BOSTON 300 LONGWOOD AVENUE BOSTON,MA02108	04-2774441	3	200,000	ACCRUAL	RESEARCH GRANT
(29) CHILDREN'S HOSPITAL OF BOSTON 300 LONGWOOD AVENUE BOSTON,MA02108	04-2774441	3	323,707	FMV	THERAPY ACCELERATION
(30) CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND,OH44195	34-0714585	3	270,000	FMV	THERAPY ACCELERATION
(31) CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND,OH44195	34-0714553	3	200,000	ACCRUAL	RESEARCH GRANT
(32) COLUMBIA UNIVERSITY MEDICAL CENTER 630 WEST 168TH STREET BOX 49 NY,NY10001	13-5598093	3	200,000	ACCRUAL	RESEARCH GRANT
(33) COLUMBIA UNIVERSITY MEDICAL CENTER 630 WEST 168TH STREET BOX 49 NY,NY10001	13-5598093	3	200,000	ACCRUAL	RESEARCH GRANT
(34) COLUMBIA UNIVERSITY MEDICAL CENTER 630 WEST 168TH STREET BOX 49 NY,NY10001	13-5598093	3	55,000	ACCRUAL	RESEARCH GRANT
(35) COLUMBIA UNIVERSITY MEDICAL CENTER 630 WEST 168TH STREET BOX 49 NY,NY10001	13-5598093	3	55,000	ACCRUAL	RESEARCH GRANT
(36) COLUMBIA UNIVERSITY MEDICAL CENTER 630 WEST 168TH STREET BOX 49 NY,NY10001	13-5598093	3	110,000	ACCRUAL	RESEARCH GRANT
(37) COLUMBIA UNIVERSITY MEDICAL CENTER 630 WEST 168TH STREET BOX 49 NY,NY10001	13-5598093	3	55,000	ACCRUAL	RESEARCH GRANT
(38) COLUMBIA UNIVERSITY MEDICAL CENTER 630 WEST 168TH STREET BOX 49 NY,NY10001	13-5598093	3	55,000	ACCRUAL	RESEARCH GRANT
(39) COLUMBIA UNIVERSITY MEDICAL CENTER 630 WEST 168TH STREET BOX 49 NY,NY10001	13-5598093	3	110,000	ACCRUAL	RESEARCH GRANT
(40) COLUMBIA UNIVERSITY MEDICAL CENTER 630 WEST 168TH STREET BOX 49 NY,NY10001	13-5598093	3	200,000	ACCRUAL	RESEARCH GRANT
(41) COLUMBIA UNIVERSITY MEDICAL CENTER 630 WEST 168TH STREET BOX 49 NY,NY10001	13-5598093	3	55,000	ACCRUAL	RESEARCH GRANT
(42) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(43) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(44) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(45) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(46) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(47) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(48) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(49) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(50) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	1,250,000	ACCRUAL	RESEARCH GRANT
(51) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(52) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(53) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(54) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(55) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(56) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(57) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(58) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(59) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(60) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(61) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(62) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(63) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(64) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(65) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(66) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(67) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(68) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	65,000	ACCRUAL	RESEARCH GRANT
(69) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(70) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	65,000	ACCRUAL	RESEARCH GRANT
(71) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(72) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(73) DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(74) DANA FARBER CANCER INSTITUTE 44 BINNEY STREET BOSTON,MA02108	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(75) DANA FARBER CANCER INSTITUTE 44 BINNEY STREET BOSTON,MA02108	04-2263040	3	55,000	ACCRUAL	RESEARCH GRANT
(76) DANA FARBER CANCER INSTITUTE 44 BINNEY STREET BOSTON,MA02108	04-2263040	3	388,850	FMV	THERAPY ACCELERATION
(77) DUKE UNIVERSITY MEDICAL CENTER 3813 BOX RESEARCH DRIVE DURHAM,NC27710	56-0532129	3	492,061	ACCRUAL	RESEARCH GRANT
(78) DUKE UNIVERSITY MEDICAL CENTER 324 BLACKWLL STREET DURHAM,NC27710	56-0532129	3	110,000	ACCRUAL	RESEARCH GRANT
(79) EMORY UNIVERSITY 201 DOWMAN DRIVE ATLANTA,GA30322	58-0566256	3	110,000	ACCRUAL	RESEARCH GRANT
(80) FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVENUE NORTH J6-500 SEATTLE,WA98109	23-7156071	3	200,000	ACCRUAL	RESEARCH GRANT
(81) FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVENUE NORTH J6-500 SEATTLE,WA98109	23-7156071	3	55,000	ACCRUAL	RESEARCH GRANT
(82) FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVENUE NORTH J6-500 SEATTLE,WA98109	23-7156071	3	55,000	ACCRUAL	RESEARCH GRANT
(83) FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVENUE NORTH J6-500 SEATTLE,WA98109	23-7156071	3	65,000	ACCRUAL	RESEARCH GRANT
(84) FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVENUE NORTH J6-500 SEATTLE,WA98109	23-7156071	3	200,000	ACCRUAL	RESEARCH GRANT
(85) GHSU RESEARCH INSTITUTE INC 1120 15TH STREET AUGUSTA,GA30912	58-1418202	3	344,189	FMV	THERAPY ACCELERATION
(86) HARVARD UNIVERSITY MASSACHUSETTS HALL CAMBRIDGE,MA02138	53-0199180	3	55,000	ACCRUAL	RESEARCH GRANT
(87) HARVARD UNIVERSITY MASSACHUSETTS HALL CAMBRIDGE,MA02138	53-0199180	3	55,000	ACCRUAL	RESEARCH GRANT
(88) HARVARD UNIVERSITY MASSACHUSETTS HALL CAMBRIDGE,MA02138	53-0199180	3	65,000	ACCRUAL	RESEARCH GRANT
(89) INDIANOPOLIS UNIVERSITY 620 UNION DRIVE ROOM 518 INDIANAPOLIS,IN46201	35-6018940	3	200,000	ACCRUAL	RESEARCH GRANT
(90) INSTITUTE OF BIOSCIENCES & TECHNOLO 400 HARVEY MITCHELL PARKWAY SOUTH COLLEGE STATION,TX77845	33-0328688	3	65,000	ACCRUAL	RESEARCH GRANT
(91) IMMUNE DISEASE INSTITUTE (AKA) THE 3 BLACKFAN CIR BOSTON,MA02115	04-2158520	3	1,250,000	ACCRUAL	RESEARCH GRANT
(92) JOHNS HOPKINS UNIVERSITY SCHOOL OF 3400 NORTH CHARLES STREET BALTIMORE,MD21201	52-0595110	3	500,000	FMV	THERAPY ACCELERATION
(93) JOHNS HOPKINS UNIVERSITY SCHOOL OF 3400 NORTH CHARLES STREET BALTIMORE,MD21201	52-0595110	3	400,000	FMV	THERAPY ACCELERATION
(94) JOHNS HOPKINS UNIVERSITY SCHOOL OF 3400 NORTH CHARLES STREET BALTIMORE,MD21201	52-0595110	3	110,000	ACCRUAL	RESEARCH GRANT
(95) JOHNS HOPKINS UNIVERSITY SCHOOL OF 3400 NORTH CHARLES STREET BALTIMORE,MD21201	52-0595110	3	65,000	ACCRUAL	RESEARCH GRANT
(96) JOHNS HOPKINS UNIVERSITY SCHOOL OF 3400 NORTH CHARLES STREET BALTIMORE,MD21201	52-0595110	3	65,000	ACCRUAL	RESEARCH GRANT
(97) JOHNS HOPKINS UNIVERSITY SCHOOL OF 3400 NORTH CHARLES STREET BALTIMORE,MD21201	52-0595110	3	110,000	ACCRUAL	RESEARCH GRANT
(98) JOHNS HOPKINS UNIVERSITY SCHOOL OF 3400 NORTH CHARLES STREET BALTIMORE,MD21201	52-0595110	3	200,000	ACCRUAL	RESEARCH GRANT
(99) JOHNS HOPKINS UNIVERSITY SCHOOL OF 3400 NORTH CHARLES STREET BALTIMORE,MD21201	52-0595110	3	110,000	ACCRUAL	RESEARCH GRANT
(100) KUMC RESEARCH INSTITUTUTE INC 3901 RAINBOW BOULEVARD MS 1039 KANSAS CITY,KS66160	48-1202402	3	300,000	FMV	THERAPY ACCELERATION
(101) LA JOLLA INSTITUTE FOR ALLERGY AND 9420 ATHENA CIRCLE LA JOLLA,CA92037	33-0328688	3	200,000	ACCRUAL	RESEARCH GRANT
(102) LA JOLLA INSTITUTE FOR ALLERGY AND 9420 ATHENA CIRCLE LA JOLLA,CA92037	33-0328688	3	65,000	ACCRUAL	RESEARCH GRANT
(103) MASSACHUSETTS GENERAL HOSPITAL 50 STANIFORD STREET BOSTON,MA02108	04-1564655	3	65,000	ACCRUAL	RESEARCH GRANT
(104) MASSACHUSETTS GENERAL HOSPITAL 50 STANIFORD STREET BOSTON,MA02108	04-1564655	3	110,000	ACCRUAL	RESEARCH GRANT
(105) MASSACHUSETTS GENERAL HOSPITAL 50 STANIFORD STREET BOSTON,MA02108	04-1564655	3	65,000	ACCRUAL	RESEARCH GRANT
(106) MASSACHUSETTS GENERAL HOSPITAL 50 STANIFORD STREET BOSTON,MA02108	04-1564655	3	110,000	ACCRUAL	RESEARCH GRANT
(107) MASSACHUSETTS GENERAL HOSPITAL 50 STANIFORD STREET BOSTON,MA02108	04-1564655	3	200,000	ACCRUAL	RESEARCH GRANT
(108) MASSACHUSETTS GENERAL HOSPITAL 50 STANIFORD STREET BOSTON,MA02108	04-1564655	3	200,000	ACCRUAL	RESEARCH GRANT
(109) MASSACHUSETTS GENERAL HOSPITAL 50 STANIFORD STREET BOSTON,MA02108	04-1564655	3	1,250,000	ACCRUAL	RESEARCH GRANT
(110) MAYO CLINIC AZ 13400 EAST SHEA BLVD SCOTTSDALE,AZ85250	86-0800150	3	200,000	ACCRUAL	RESEARCH GRANT
(111) MAYO CLINIC AZ 13400 EAST SHEA BLVD SCOTTSDALE,AZ85250	86-0800150	3	200,000	ACCRUAL	RESEARCH GRANT
(112) MAYO CLINIC AZ 13400 EAST SHEA BLVD SCOTTSDALE,AZ85250	86-0800150	3	200,000	ACCRUAL	RESEARCH GRANT
(113) MAYO CLINIC AZ 13400 EAST SHEA BLVD SCOTTSDALE,AZ85250	86-0800150	3	200,000	ACCRUAL	RESEARCH GRANT
(114) MAYO CLINIC ROCHESTER 200 FIRST STREET SW ROCHESTER,MN55905	41-6011702	3	110,000	ACCRUAL	RESEARCH GRANT
(115) MAYO CLINIC ROCHESTER 200 FIRST STREET SW ROCHESTER,MN55905	41-6011702	3	200,000	ACCRUAL	RESEARCH GRANT
(116) MAYO CLINIC ROCHESTER 200 FIRST STREET SW ROCHESTER,MN55905	41-6011702	3	110,000	ACCRUAL	RESEARCH GRANT
(117) MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON,TX77030	74-6001118	3	55,000	ACCRUAL	RESEARCH GRANT
(118) MEDICAL COLLEGE OF WI INC 8701 WATERTOWN PLANK RD PO BOX 2 MILWAUKEE,WI53226	39-0806261	3	110,000	ACCRUAL	RESEARCH GRANT
(119) MEMORIAL SLOAN KETTERING 633 THIRD AVENUE NEW YORK,NY10017	91-2154267	3	114,350	FMV	THERAPY ACCELERATION
(120) MOFFITT CANCER CENTER AND RESEARCH 12902 MAGNOLIA DR TAMPA,FL33612	59-2451713	3	65,000	ACCRUAL	RESEARCH GRANT
(121) MOUNT SINAI SCHOOL OF MEDICINE 1079 ONE GUSTAVE L LEVY PLACE NY,NY10029	13-6171197	3	1,250,000	ACCRUAL	RESEARCH GRANT
(122) MOUNT SINAI SCHOOL OF MEDICINE 1428 MADISON AVENUE NY,NY10029	13-6171197	3	200,000	ACCRUAL	RESEARCH GRANT
(123) MOUNT SINAI SCHOOL OF MEDICINE 1428 MADISON AVENUE NY,NY10029	13-6171197	3	110,000	ACCRUAL	RESEARCH GRANT
(124) NATIONAL INSTITUTES OF HEALTH NIH 6705 ROCKLEDGE DR BETHESDA,MD20892	52-0858115	3	55,000	ACCRUAL	RESEARCH GRANT
(125) NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE CHICAGO,IL60601	36-2656113	3	200,000	ACCRUAL	RESEARCH GRANT
(126) NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE CHICAGO,IL60601	36-2656113	3	200,000	ACCRUAL	RESEARCH GRANT
(127) NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE CHICAGO,IL60601	36-2656113	3	200,000	ACCRUAL	RESEARCH GRANT
(128) NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE CHICAGO,IL60601	36-2656113	3	1,250,000	ACCRUAL	RESEARCH GRANT
(129) NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE CHICAGO,IL60601	36-2656113	3	55,000	ACCRUAL	RESEARCH GRANT
(130) NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE CHICAGO,IL60601	36-2656113	3	65,000	ACCRUAL	RESEARCH GRANT
(131) NY UNIVERSITY SCHOOL OF MEDICINE 545 FIRST AVENUE GBH SC1-55 NY,NY10001	13-6171197	3	1,250,000	ACCRUAL	RESEARCH GRANT
(132) NY UNIVERSITY SCHOOL OF MEDICINE 545 FIRST AVENUE GBH SC1-55 NY,NY10001	13-6171197	3	65,000	ACCRUAL	RESEARCH GRANT
(133) NY UNIVERSITY SCHOOL OF MEDICINE 545 FIRST AVENUE GBH SC1-55 NY,NY10001	13-6171197	3	200,000	ACCRUAL	RESEARCH GRANT
(134) NY UNIVERSITY SCHOOL OF MEDICINE 545 FIRST AVENUE GBH SC1-55 NY,NY10001	13-6171197	3	200,000	ACCRUAL	RESEARCH GRANT
(135) NY UNIVERSITY SCHOOL OF MEDICINE 545 FIRST AVENUE GBH SC1-55 NY,NY10001	13-6171197	3	65,000	ACCRUAL	RESEARCH GRANT
(136) NY UNIVERSITY SCHOOL OF MEDICINE 545 FIRST AVENUE GBH SC1-55 NY,NY10001	13-6171197	3	110,000	ACCRUAL	RESEARCH GRANT
(137) OHIO STATE UNIVERSITY 281 W LANE AVENUE COLUMBUS,OH43210	31-6401599	3	65,000	ACCRUAL	RESEARCH GRANT
(138) OHIO STATE UNIVERSITY 281 W LANE AVENUE COLUMBUS,OH43210	31-6401599	3	65,000	ACCRUAL	RESEARCH GRANT
(139) OHIO STATE UNIVERSITY 281 W LANE AVENUE COLUMBUS,OH43210	31-6401599	3	200,000	ACCRUAL	RESEARCH GRANT
(140) OHIO STATE UNIVERSITY 281 W LANE AVENUE COLUMBUS,OH43210	31-6401599	3	200,000	ACCRUAL	RESEARCH GRANT
(141) OHIO STATE UNIVERSITY 281 W LANE AVENUE COLUMBUS,OH43210	31-6401599	3	1,250,000	ACCRUAL	RESEARCH GRANT
(142) OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND,OR97239	23-7083114	3	55,000	ACCRUAL	RESEARCH GRANT
(143) OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND,OR97239	23-7083114	3	1,250,000	ACCRUAL	RESEARCH GRANT
(144) OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD PORTLAND,OR97239	23-7083114	3	2,222,000	FMV	THERAPY ACCELERATION
(145) PENNSYLVANIA STATE UNIVERSITY 123 S BURROWES ST STATE COLLEGE,PA16801	23-1352685	3	200,000	ACCRUAL	RESEARCH GRANT
(146) PRESIDENT & FELLOWS OF HARVARD COLL 6TH FLOOR HOLYOKE CENTER 1350 MA A CAMBRIDGE,MA02138	04-2103580	3	200,000	ACCRUAL	RESEARCH GRANT
(147) PRINCETON UNIVERSITY 200 ELM DRIVE PRINCETON,NJ08544	21-0634501	3	335,145	ACCRUAL	RESEARCH GRANT
(148) REGENTS OF THE UNIVERSITY OF MN - T 450 MCNAMARA ALUMNI CENTER 200 OAK MINNEAPOLIS,MN55401	41-6007513	3	200,000	ACCRUAL	RESEARCH GRANT
(149) RHODE ISLAND HOSPITAL 593 EDDY STREET ALDRICH 3-317 PROVIDENCE,RI02903	26-3020947	3	65,000	ACCRUAL	RESEARCH GRANT
(150) ROBERT WOOD JOHNSON MEDICAL SCHOOL 335 GEORGE STREET LIBERTY PLAZA 4T NEW BRUNSWICK,NJ08901	22-1776306	3	200,000	ACCRUAL	RESEARCH GRANT
(151) ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NY,NY10065	13-1624158	3	55,000	ACCRUAL	RESEARCH GRANT
(152) ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NY,NY10065	13-1624158	3	65,000	ACCRUAL	RESEARCH GRANT
(153) ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NY,NY10065	13-1624158	3	55,000	ACCRUAL	RESEARCH GRANT
(154) ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NY,NY10065	13-1624158	3	55,000	ACCRUAL	RESEARCH GRANT
(155) ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NY,NY10065	13-1624158	3	55,000	ACCRUAL	RESEARCH GRANT
(156) SAINT JUDE CHILDREN'S RESEARCH HOSP 262 DANNY THOMAS PLACE MEMPHIS,TN38105	62-0646012	3	65,000	ACCRUAL	RESEARCH GRANT
(157) SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA,CA92037	33-0435954	3	110,000	ACCRUAL	RESEARCH GRANT
(158) SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA,CA92037	33-0435954	3	110,000	ACCRUAL	RESEARCH GRANT
(159) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10001	91-2154267	3	55,000	ACCRUAL	RESEARCH GRANT
(160) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10001	91-2154267	3	55,000	ACCRUAL	RESEARCH GRANT
(161) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10001	91-2154267	3	110,000	ACCRUAL	RESEARCH GRANT
(162) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10001	91-2154267	3	200,000	ACCRUAL	RESEARCH GRANT
(163) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10001	91-2154267	3	200,000	ACCRUAL	RESEARCH GRANT
(164) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10001	91-2154267	3	65,000	ACCRUAL	RESEARCH GRANT
(165) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10001	91-2154267	3	65,000	ACCRUAL	RESEARCH GRANT
(166) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10001	91-2154267	3	200,000	ACCRUAL	RESEARCH GRANT
(167) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10001	91-2154267	3	55,000	ACCRUAL	RESEARCH GRANT
(168) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10001	91-2154267	3	110,000	ACCRUAL	RESEARCH GRANT
(169) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10065	91-2154267	3	55,000	ACCRUAL	RESEARCH GRANT
(170) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10065	91-2154267	3	110,000	ACCRUAL	RESEARCH GRANT
(171) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10065	91-2154267	3	500,000	ACCRUAL	RESEARCH GRANT
(172) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10065	91-2154267	3	110,000	ACCRUAL	RESEARCH GRANT
(173) SLOAN-KETTERING INSTITUTE FOR CANCE 1275 YORK AVENUE NY,NY10065	91-2154267	3	55,000	ACCRUAL	RESEARCH GRANT
(174) SAINT LOUIS UNIVERSITY 3700 WEST PINE MALL ST LOUIS,MO63104	43-0654872	3	200,000	ACCRUAL	RESEARCH GRANT
(175) STANFORD UNIVERSITY 9500 GILMAN DRIVE LA JOLLA,CA92037	23-7121131	3	110,000	ACCRUAL	RESEARCH GRANT
(176) STANFORD UNIVERSITY 9500 GILMAN DRIVE LA JOLLA,CA92037	23-7121131	3	200,000	ACCRUAL	RESEARCH GRANT
(177) STANFORD UNIVERSITY 340 PANAMA STREET STANFORD,CA94305	23-7121131	3	55,000	ACCRUAL	RESEARCH GRANT
(178) STANFORD UNIVERSITY 340 PANAMA STREET STANFORD,CA94305	23-7121131	3	500,000	ACCRUAL	RESEARCH GRANT
(179) STANFORD UNIVERSITY 340 PANAMA STREET STANFORD,CA94305	23-7121131	3	200,000	ACCRUAL	RESEARCH GRANT
(180) STANFORD UNIVERSITY 340 PANAMA STREET STANFORD,CA94305	23-7121131	3	110,000	ACCRUAL	RESEARCH GRANT
(181) STANFORD UNIVERSITY 340 PANAMA STREET STANFORD,CA94305	23-7121131	3	55,000	ACCRUAL	RESEARCH GRANT
(182) STANFORD UNIVERSITY 340 PANAMA STREET STANFORD,CA94305	23-7121131	3	100,000	ACCRUAL	RESEARCH GRANT
(183) STANFORD UNIVERSITY MEDICAL CENTER 301 RAVENSWOOD AVENUE MAIL CODE 55 MENLO PARK,CA94025	23-7121131	3	65,000	ACCRUAL	RESEARCH GRANT
(184) STANFORD UNIVERSITY MEDICAL CENTER 301 RAVENSWOOD AVENUE MAIL CODE 55 MENLO PARK,CA94025	23-7121131	3	55,000	ACCRUAL	RESEARCH GRANT
(185) STANFORD UNIVERSITY MEDICAL CENTER 301 RAVENSWOOD AVENUE MAIL CODE 55 MENLO PARK,CA94025	23-7121131	3	65,000	ACCRUAL	RESEARCH GRANT
(186) STANFORD UNIVERSITY MEDICAL CENTER 301 RAVENSWOOD AVENUE MAIL CODE 55 MENLO PARK,CA94025	23-7121131	3	65,000	ACCRUAL	RESEARCH GRANT
(187) STOWERS INSTITUTE FOR MEDICAL RESEA 1000 EAST 50TH STREET KANSAS CITY,MO64110	43-1684454	3	55,000	ACCRUAL	RESEARCH GRANT
(188) SUNY UPSTATE MEDICAL UNIVERSITY 750 EAST ADAMS STREET SYRACUSE,NY13210	14-1368361	3	200,000	ACCRUAL	RESEARCH GRANT
(189) SUNY UPSTATE MEDICAL UNIVERSITY - S 750 E ADAMS ST SYRACUSE,NY13210	14-1368361	3	110,000	ACCRUAL	RESEARCH GRANT
(190) TEMPLE UNIVERSITY 3400N BOARD STREET PHILADELPHIA,PA19140	23-1365971	3	200,000	ACCRUAL	RESEARCH GRANT
(191) THE BOARD OF TRUSTEES OF THE UNIVER 809 S MARSHFIELD AVENUE M/C 551 CHICAGO,IL60607	37-6000511	3	110,000	ACCRUAL	RESEARCH GRANT
(192) THE CHILDREN'S HOSPITAL OF PHILADEL 3615 CIVIC CENTER BLVD PHILADELPHIA,PA19104	23-1352166	3	110,000	ACCRUAL	RESEARCH GRANT
(193) THE CHILDREN'S HOSPITAL OF PHILADEL 3615 CIVIC CENTER BLVD PHILADELPHIA,PA19104	23-1352166	3	110,000	ACCRUAL	RESEARCH GRANT
(194) THE HOSPITAL FOR SPECIAL SURGERY 535 EAST 70TH STREET NY,NY10021	13-6714749	3	200,000	ACCRUAL	RESEARCH GRANT
(195) THE OHIO STATE UNIVERSITY 320 WEST 10TH AVENUE COLUMBUS,OH43210	31-6401599	3	1,250,000	ACCRUAL	RESEARCH GRANT
(196) THE REGENTS OF THE UNIVERSITY OF CA 2150 SHATTUCK AVENUE BERKELEY,CA94720	94-6002123	3	65,000	ACCRUAL	RESEARCH GRANT
(197) THE REGENTS OF THE UNIVERSITY OF CA 2150 SHATTUCK AVENUE BERKELEY,CA94720	94-6002123	3	65,000	ACCRUAL	RESEARCH GRANT
(198) THE REGENTS OF THE UNIVERSITY OF CA 2150 SHATTUCK AVENUE BERKELEY,CA94720	94-6002123	3	55,000	ACCRUAL	RESEARCH GRANT
(199) THE REGENTS OF THE UNIVERSITY OF CA 11000 KINROSS AVENUE SUITE 102 LOS ANGELES,CA90095	95-6006143	3	65,000	ACCRUAL	RESEARCH GRANT
(200) THE REGENTS OF THE UNIVERSITY OF CA 11000 KINROSS AVENUE SUITE 102 LOS ANGELES,CA90095	95-6006143	3	110,000	ACCRUAL	RESEARCH GRANT
(201) THE REGENTS OF THE UNIVERSITY OF CA 11000 KINROSS AVENUE SUITE 102 LOS ANGELES,CA90095	95-6006143	3	55,000	ACCRUAL	RESEARCH GRANT
(202) THE REGENTS OF THE UNIVERSITY OF CA 11000 KINROSS AVENUE SUITE 102 LOS ANGELES,CA90095	95-6006143	3	200,000	ACCRUAL	RESEARCH GRANT
(203) THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DRIVE LA JOLLA,CA92093	95-2872494	3	1,250,000	ACCRUAL	RESEARCH GRANT
(204) THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DRIVE LA JOLLA,CA92093	95-2872494	3	110,000	ACCRUAL	RESEARCH GRANT
(205) THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DRIVE LA JOLLA,CA92093	95-2872494	3	55,000	ACCRUAL	RESEARCH GRANT
(206) THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DRIVE LA JOLLA,CA92093	95-2872494	3	110,000	ACCRUAL	RESEARCH GRANT
(207) THE REGENTS OF THE UNIVERSITY OF CA 9500 GILMAN DRIVE LA JOLLA,CA92093	95-2872494	3	110,000	ACCRUAL	RESEARCH GRANT
(208) THE REGENTS OF THE UNIVERSITY OF CA 505 PARNASSUS AVENUE SUITE M1286 B SAN FRANCISCO,CA94143	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(209) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(210) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	65,000	ACCRUAL	RESEARCH GRANT
(211) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	200,000	ACCRUAL	RESEARCH GRANT
(212) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	200,000	ACCRUAL	RESEARCH GRANT
(213) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	65,000	ACCRUAL	RESEARCH GRANT
(214) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	110,000	ACCRUAL	RESEARCH GRANT
(215) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	110,000	ACCRUAL	RESEARCH GRANT
(216) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	200,000	ACCRUAL	RESEARCH GRANT
(217) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	200,000	ACCRUAL	RESEARCH GRANT
(218) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	110,000	ACCRUAL	RESEARCH GRANT
(219) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	200,000	ACCRUAL	RESEARCH GRANT
(220) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	110,000	ACCRUAL	RESEARCH GRANT
(221) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(222) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(223) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	110,000	ACCRUAL	RESEARCH GRANT
(224) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(225) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	110,000	ACCRUAL	RESEARCH GRANT
(226) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	200,000	ACCRUAL	RESEARCH GRANT
(227) THE REGENTS OF THE UNIVERSITY OF CA 1111 FRANKLIN ST OAKLAND,CA94607	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(228) THE REGENTS OF THE UNIVERSITY OF MI 515 E JEFFERSON ST ANN ARBOR,MI48109	38-6006309	3	200,000	ACCRUAL	RESEARCH GRANT
(229) THE REGENTS OF THE UNIVERSITY OF MI 515 E JEFFERSON ST ANN ARBOR,MI48109	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(230) THE REGENTS OF THE UNIVERSITY OF MI 515 E JEFFERSON ST ANN ARBOR,MI48109	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(231) THE REGENTS OF THE UNIVERSITY OF MI 515 E JEFFERSON ST ANN ARBOR,MI48109	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(232) THE REGENTS OF THE UNIVERSITY OF MI 515 E JEFFERSON ST ANN ARBOR,MI48109	38-6006309	3	200,000	ACCRUAL	RESEARCH GRANT
(233) THE REGENTS OF THE UNIVERSITY OF MI 515 E JEFFERSON ST ANN ARBOR,MI48109	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(234) THE REGENTS OF THE UNIVERSITY OF MI 515 E JEFFERSON ST ANN ARBOR,MI48109	38-6006309	3	200,000	ACCRUAL	RESEARCH GRANT
(235) THE REGENTS OF THE UNIVERSITY OF MI 515 E JEFFERSON ST ANN ARBOR,MI48109	38-6006309	3	200,000	ACCRUAL	RESEARCH GRANT
(236) THE REGENTS OF THE UNIVERSITY OF MI 515 E JEFFERSON ST ANN ARBOR,MI48109	38-6006309	3	200,000	ACCRUAL	RESEARCH GRANT
(237) THE REGENTS OF THE UNIVERSITY OF MI 515 E JEFFERSON ST ANN ARBOR,MI48109	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(238) THE REGENTS OF THE UNIVERSITY OF MI 515 E JEFFERSON ST ANN ARBOR,MI48109	38-6006309	3	200,000	ACCRUAL	RESEARCH GRANT
(239) THE REGENTS OF THE UNIVERSITY OF MI 515 E JEFFERSON ST ANN ARBOR,MI48109	38-6006309	3	50,000	ACCRUAL	RESEARCH GRANT
(240) THE REGENTS OF THE UNIVERSITY OF MI 1500 E MEDICAL CENTER DRIVE ANN ARBOR,MI48109	38-6006309	3	974,091	FMV	THERAPY ACCELERATION
(241) THE RESEARCH INSTITUTE OF FOX CHASE 333 COTTMAN AVENUE PHILADELPHIA,PA19111	23-2003072	3	200,000	ACCRUAL	RESEARCH GRANT
(242) THE TRUSTEES OF THE UNIVERSITY OF P 3451 WALNUT STREET PHILADELPHIA,PA19104	23-1352685	3	200,000	ACCRUAL	RESEARCH GRANT
(243) THE TRUSTEES OF THE UNIVERSITY OF P 3451 WALNUT STREET PHILADELPHIA,PA19104	23-1352685	3	1,250,000	ACCRUAL	RESEARCH GRANT
(244) THE TRUSTEES OF THE UNIVERSITY OF P 3451 WALNUT STREET PHILADELPHIA,PA19104	23-1352685	3	200,000	ACCRUAL	RESEARCH GRANT
(245) THE TRUSTEES OF THE UNIVERSITY OF P 3451 WALNUT STREET PHILADELPHIA,PA19104	23-1352685	3	65,000	ACCRUAL	RESEARCH GRANT
(246) THE TRUSTEES OF THE UNIVERSITY OF P 3451 WALNUT STREET PHILADELPHIA,PA19104	23-1352685	3	65,000	ACCRUAL	RESEARCH GRANT
(247) THE UNIVERSITY OF CHICAGO 900 EAST 57TH STREET CHICAGO,IL60601	36-2177139	3	100,000	ACCRUAL	RESEARCH GRANT
(248) THE UNIVERSITY OF CHICAGO 6030 S ELLIS AVE CHICAGO,IL60601	36-2177139	3	200,000	ACCRUAL	RESEARCH GRANT
(249) THE UNIVERSITY OF CHICAGO 6030 S ELLIS AVE CHICAGO,IL60601	36-2177139	3	55,000	ACCRUAL	RESEARCH GRANT
(250) THE UNIVERSITY OF CHICAGO 6030 S ELLIS AVE CHICAGO,IL60601	36-2177139	3	200,000	ACCRUAL	RESEARCH GRANT
(251) THE UNIVERSITY OF CHICAGO 6030 S ELLIS AVE CHICAGO,IL60601	36-2177139	3	200,000	ACCRUAL	RESEARCH GRANT
(252) TRUSTEES OF DARTMOUTH COLLEGE 6010 PARKHURST HALL SUITE 204 HANOVER,NH03755	02-0222111	3	200,000	ACCRUAL	RESEARCH GRANT
(253) UNIV OF TX HEALTH SCIENCE CENTER AT 7703 FLOYD CURL DRIVE SAN ANTONIO,TX78229	04-2263040	3	200,000	ACCRUAL	RESEARCH GRANT
(254) UNIVERSITY OF ALABAMA AT BIRMINGHAM 1720 2ND AVENUE SOUTH BIRMINGHAM,AL35294	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(255) UNIVERSITY OF ARKANSAS FOR MEDICAL 4301 W MARKHAM ST LITTLE ROCK,AR72205	71-6046242	3	200,000	ACCRUAL	RESEARCH GRANT
(256) UNIVERSITY OF CA AT SAN FRANCISCO 3333 CA ST SUITE 315 SAN FRANCISCO,CA94143	94-6036493	3	55,000	ACCRUAL	RESEARCH GRANT
(257) UNIVERSITY OF CALIFORNIA SAN FRANC 500 PARNASSUS AVE SAN FRANCISCO,CA94143	95-1690977	3	110,000	ACCRUAL	RESEARCH GRANT
(258) UNIVERSITY OF CINCINNATI 51 GOODMAN DRIVE UNIVERSITY HALL S CINCINNATI,OH45201	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(259) UNIVERSITY OF COLORADO 3415 COLORADO AVE UCB 596 AURORA,CO80045	84-6000555	3	37,500	ACCRUAL	RESEARCH GRANT
(260) UNIVERSITY OF COLORADO 1250 14TH STREET DENVER,CO80291	84-6000555	3	225,000	FMV	THERAPY ACCELERATION
(261) UNIVERSITY OF COLORADO AT BOULDER 3100 MARINE STREET BOULDER,CO80303	84-6000555	3	55,000	ACCRUAL	RESEARCH GRANT
(262) UNIVERSITY OF COLORADO DENVER ANSC 13001 E 17TH PLACE AURORA,CO80045	87-6000525	3	200,000	ACCRUAL	RESEARCH GRANT
(263) UNIVERSITY OF FLORIDA 113001 PO BOX GAINESVILLE,FL32601	59-6002052	3	835,253	ACCRUAL	RESEARCH GRANT
(264) UNIVERSITY OF FLORIDA GAINESVILLE GAINESVILLE,FL32611	59-6002052	3	110,000	ACCRUAL	RESEARCH GRANT
(265) UNIVERSITY OF FLORIDA GAINESVILLE GAINESVILLE,FL32601	59-6002052	3	200,000	ACCRUAL	RESEARCH GRANT
(266) UNIVERSITY OF MA MEDICAL SCHOOL 364 PLANTATION STREET WORCESTER,MA01605	04-3167352	3	55,000	ACCRUAL	RESEARCH GRANT
(267) UNIVERSITY OF MA MEDICAL SCHOOL 364 PLANTATION STREET WORCESTER,MA01605	04-3167352	3	110,000	ACCRUAL	RESEARCH GRANT
(268) UNIVERSITY OF MD BALTIMORE 220 ARCH STREET OFFICE LEVEL 2 RO BALTIMORE,MD21201	52-6002033	3	200,000	ACCRUAL	RESEARCH GRANT
(269) UNIVERSITY OF MD BALTIMORE 220 ARCH STREET OFFICE LEVEL 2 RO BALTIMORE,MD21201	52-6002033	3	200,000	ACCRUAL	RESEARCH GRANT
(270) UNIVERSITY OF MICHIGAN 1500 E MEDICAL CENTER DRIVE ANN ARBOR,MI48109	38-6006309	3	200,000	ACCRUAL	RESEARCH GRANT
(271) UNIVERSITY OF MICHIGAN 1500 E MEDICAL CENTER DRIVE ANN ARBOR,MI48109	38-6006309	3	200,000	ACCRUAL	RESEARCH GRANT
(272) UNIVERSITY OF MICHIGAN 1500 E MEDICAL CENTER DRIVE ANN ARBOR,MI48109	38-6006309	3	110,000	ACCRUAL	RESEARCH GRANT
(273) UNIVERSITY OF MICHIGAN 1600 HURON PARKWAY 2ND FLOOR ANN ARBOR,MI48109	38-6006309	3	34,982	FMV	THERAPY ACCELERATION
(274) UNIVERSITY OF MN TWIN CITIES 321 CHURCH STREET SE MINNEAPOLIS,MN55401	76-0300816	3	110,000	ACCRUAL	RESEARCH GRANT
(275) UNIVERSITY OF NEBRASKA MEDICAL CENT 985100 NEBRASKA MEDICAL CENTER OMAHA,NE68105	47-0049123	3	200,000	ACCRUAL	RESEARCH GRANT
(276) UNIVERSITY OF NORTH CAROLINA AT CHA 450 WEST DRIVE CHAPEL HILL,NC27599	56-6001393	3	55,000	ACCRUAL	RESEARCH GRANT
(277) UNIVERSITY OF PENNSYLVANIA 421 CURIE BOULEVARD BRBII/IIIRM 53 PHILADELPHIA,PA19104	23-1352685	3	200,000	ACCRUAL	RESEARCH GRANT
(278) UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA,PA19104	23-1352685	3	55,000	ACCRUAL	RESEARCH GRANT
(279) UNIVERSITY OF ROCHESTER 601 ELMWOOD AVENUE ROCHESTER,NY14603	16-0473209	3	200,000	ACCRUAL	RESEARCH GRANT
(280) UNIVERSITY OF ROCHESTER 601 ELMWOOD AVENUE ROCHESTER,NY14603	16-0473209	3	200,000	ACCRUAL	RESEARCH GRANT
(281) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	76-0300816	3	110,000	ACCRUAL	RESEARCH GRANT
(282) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	76-0300816	3	200,000	ACCRUAL	RESEARCH GRANT
(283) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	76-0300816	3	110,000	ACCRUAL	RESEARCH GRANT
(284) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	76-0300816	3	110,000	ACCRUAL	RESEARCH GRANT
(285) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	76-0300816	3	110,000	ACCRUAL	RESEARCH GRANT
(286) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	76-0300816	3	200,000	ACCRUAL	RESEARCH GRANT
(287) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	76-0300816	3	500,000	ACCRUAL	RESEARCH GRANT
(288) UNIVERSITY OF TX MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON,TX77030	76-0300816	3	200,000	ACCRUAL	RESEARCH GRANT
(289) UNIVERSITY OF UTAH 30 NORTH 1900E RM 1C26 SOM SALT LAKE CITY,UT84112	87-6000525	3	200,000	ACCRUAL	RESEARCH GRANT
(290) UNIVERSITY OF UTAH 30 NORTH 1900E RM 1C26 SOM SALT LAKE CITY,UT84112	87-6000525	3	55,000	ACCRUAL	RESEARCH GRANT
(291) UNIVERSITY OF UTAH 30 NORTH 1900E RM 1C26 SOM SALT LAKE CITY,UT84112	87-6000525	3	200,000	ACCRUAL	RESEARCH GRANT
(292) UNIVERSITY OF UTAH 30 NORTH 1900E RM 1C26 SOM SALT LAKE CITY,UT84112	87-6000525	3	200,000	ACCRUAL	RESEARCH GRANT
(293) UNIVERSITY OF UTAH 30 NORTH 1900E RM 1C26 SOM SALT LAKE CITY,UT84112	87-6000525	3	200,000	ACCRUAL	RESEARCH GRANT
(294) UNIVERSITY OF UTAH 30 NORTH 1900E RM 1C26 SOM SALT LAKE CITY,UT84112	87-6000525	3	110,000	ACCRUAL	RESEARCH GRANT
(295) UNIVERSITY OF WASHINGTON 1100 NE 45TH STREET SEATTLE,WA98105	91-6001537	3	200,000	ACCRUAL	RESEARCH GRANT
(296) UNIVERSITY OF WASHINGTON 1100 NE 45TH STREET SEATTLE,WA98105	91-6001537	3	55,000	ACCRUAL	RESEARCH GRANT
(297) UNIVERSITY OF WASHINGTON 1100 NE 45TH STREET SEATTLE,WA98105	91-6001537	3	110,000	ACCRUAL	RESEARCH GRANT
(298) UNIVERSITY OF WI-MADISON (BOARD OF 750 UNIVERSITY AVENUE MADISON,WI53706	04-2263040	3	110,000	ACCRUAL	RESEARCH GRANT
(299) UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS,TX75390	76-0300816	3	110,000	ACCRUAL	RESEARCH GRANT
(300) UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS,TX75390	76-0300816	3	110,000	ACCRUAL	RESEARCH GRANT
(301) UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS,TX75390	76-0300816	3	200,000	ACCRUAL	RESEARCH GRANT
(302) UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS,TX75390	76-0300816	3	55,000	ACCRUAL	RESEARCH GRANT
(303) VANDERBILT UNIVERSITY MEDICAL CENTE 3319 WEST END AVENUE SUITE 800 NASHVILLE,TN37232	62-0476822	3	110,000	ACCRUAL	RESEARCH GRANT
(304) VIRGINIA COMMONWEALTH UNIVERSITY 401 COLLEGE STREET RICHMOND,VA23298	54-6001758	3	200,000	ACCRUAL	RESEARCH GRANT
(305) WA UNIVERSITY OF SAINT LOUIS 660 SOUTH EUCLID AVENUE ST LOUIS,MO63110	43-0653611	3	110,000	ACCRUAL	RESEARCH GRANT
(306) WAKE FOREST UNIVERSITY 1834 WAKE FOREST ROAD WINSTONSALEM,NC27106	22-3849199	3	200,000	ACCRUAL	RESEARCH GRANT
(307) WEILL MEDICAL COLLEGE OF CORNELL UN 575 LEXINGTON AVENUE 9TH FLOOR NY,NY10001	13-3376695	3	200,000	ACCRUAL	RESEARCH GRANT
(308) WEILL MEDICAL COLLEGE OF CORNELL UN 575 LEXINGTON AVENUE 9TH FLOOR NY,NY10001	13-3376695	3	55,000	ACCRUAL	RESEARCH GRANT
(309) WEILL MEDICAL COLLEGE OF CORNELL UN 575 LEXINGTON AVENUE 9TH FLOOR NY,NY10001	13-3376695	3	200,000	ACCRUAL	RESEARCH GRANT
(310) WEILL MEDICAL COLLEGE OF CORNELL UN 575 LEXINGTON AVENUE 9TH FLOOR NY,NY10001	13-3376695	3	200,000	ACCRUAL	RESEARCH GRANT
(311) WEILL MEDICAL COLLEGE OF CORNELL UN 575 LEXINGTON AVENUE 9TH FLOOR NY,NY10001	13-3376695	3	200,000	ACCRUAL	RESEARCH GRANT
(312) WEILL MEDICAL COLLEGE OF CORNELL UN 575 LEXINGTON AVENUE 9TH FLOOR NY,NY10001	13-3376695	3	200,000	ACCRUAL	RESEARCH GRANT
(313) WEILL MEDICAL COLLEGE OF CORNELL UN 575 LEXINGTON AVENUE 9TH FLOOR NY,NY10001	13-3376695	3	200,000	ACCRUAL	RESEARCH GRANT
(314) WEILL MEDICAL COLLEGE OF CORNELL UN 575 LEXINGTON AVENUE 9TH FLOOR NY,NY10001	13-3376695	3	110,000	ACCRUAL	RESEARCH GRANT
(315) WEILL MEDICAL COLLEGE OF CORNELL UN 575 LEXINGTON AVENUE 9TH FLOOR NY,NY10001	13-3376695	3	55,000	ACCRUAL	RESEARCH GRANT
(316) WHITEHEAD INSTITUTE FOR BIOMEDICAL 9 CAMBRIDGE CENTER CAMBRIDGE,MA02138	06-1043412	3	110,000	ACCRUAL	RESEARCH GRANT
(317) WHITEHEAD INSTITUTE FOR BIOMEDICAL 9 CAMBRIDGE CENTER CAMBRIDGE,MA02138	06-1043412	3	65,000	ACCRUAL	RESEARCH GRANT
(318) WHITEHEAD INSTITUTE FOR BIOMEDICAL 9 CAMBRIDGE CENTER CAMBRIDGE,MA02138	06-1043412	3	55,000	ACCRUAL	RESEARCH GRANT
(319) YALE UNIVERSITY 155 WHITNEY AVENUE PO BOX 208250 NEW HAVEN,CT06510	06-0646973	3	55,000	ACCRUAL	RESEARCH GRANT
(320) YALE UNIVERSITY 155 WHITNEY AVENUE PO BOX 208250 NEW HAVEN,CT06510	06-0646973	3	55,000	ACCRUAL	RESEARCH GRANT
(321) YALE UNIVERSITY 208250 PO BOX NEW HAVEN,CT06510	06-0646973	3	200,000	ACCRUAL	RESEARCH GRANT
(322) ACETYLON PHARMACEUTICALS 70 FARGO STREET BOSTON,MA02210	26-3506788		740,000	FMV	THERAPY ACCELERATION
(323) BECKLOFF ASSOCIATES INC 3203 SOLUTIONS CENTER CHICAGO,IL60677	48-0842223		25,000	FMV	THERAPY ACCELERATION
(324) BIOSYNTHESIS INC 612 EAST MAIN STREET LEWISVILLE,TX75067	75-2297191		24,400	FMV	THERAPY ACCELERATION
(325) CELATOR PHARMACEUTICALS 303B COLLEGE ROAD EAST PRINCETON,NJ08540	20-2680869		740,275	FMV	THERAPY ACCELERATION
(326) CONSTELLATION PHARMACEUTICALS 215 FIRST STREET SUITE 200 CAMBRIDGE,MA02142	26-1741721		2,000,000	FMV	THERAPY ACCELERATION
(327) CURIS INC 4 MAGUIRE ROAD LEXINGTON,MA02421	04-3505116		1,650,000	FMV	THERAPY ACCELERATION
(328) ONCONOVA THERAPEUTICS 375 PHEASANT RUN NEWTOWN,PA18940	22-3627252		500,000	FMV	THERAPY ACCELERATION
(329) INTEGRATED ANALYTICAL SOLUTION 1456 FOURTH STREET UNIT C BERKELEY,CA94710	20-0776697		11,025	FMV	THERAPY ACCELERATION
(330) MICROCONSTANTS INC 9050 CAMINO SANTA FE SAN DIEGO,CA92121	33-0809500		57,895	FMV	THERAPY ACCELERATION
(331) NANOSYN 3100 CENTRAL EXPRESSWAY SANTA CLARA,CA95051	86-0909295		627,175	FMV	THERAPY ACCELERATION
(332) PEPTISYNTHA INC 23424 NETWORK PLACE CHICAGO,IL60673	76-0315292		31,772	FMV	THERAPY ACCELERATION
(333) SHAPE 55 CAMBRIDGE PARKWAY CAMBRIDGE,MA02142	26-3714475		300,000	FMV	THERAPY ACCELERATION
(334) SMITHERS PHARMA SERVICES 75711 PO BOX CLEVELAND,OH44101	20-1922115		10,500	FMV	THERAPY ACCELERATION
(335) VALOR BIOTHERAPEUTICS 15922 PO BOX COLLEGE STATION,TX77841	46-1883738		1,300,000	FMV	THERAPY ACCELERATION

Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ................ Bullet Image

321

Enter total number of other organizations listed in the line 1 table ........................ . Bullet Image

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50055P

Schedule I (Form 990) 2012

Page 2

Part III

Grants and Other Assistance to Individuals in the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 22.
Part III can be duplicated if additional space is needed.

(a)Type of grant or assistance	(b)Number of recipients	(c)Amount of cash grant
(1) PATIENT AID	29894	2,989,442
(2) COPAY ASSISTANCE CML	705	900,000
(3) COPAY ASSISTANCE CLL	2106	3,135,550
(4) COPAY ASSISTANCE LYMPHOMA	8230	10,984,800
(5) COPAY ASSISTANCE MDS	1473	4,320,000
(6) COPAY ASSISTANCE MYELOMA	5745	23,310,000

Part IV

Supplemental Information.

Complete this part to provide the information required in Part I, line 2, Part III, column (b), and any other additional information.

Identifier	Return Reference	Explanation
PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS INSIDE THE UNITED STATES	SCHEDULE I, PAGE 1, PART I, LINE 2	FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS,EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT.

Schedule I (Form 990) 2012

Additional Data

Software ID:
Software Version:

- TIN:

Schedule J
(Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet

Complete if the organization answered "Yes" to Form 990,
Part IV, question 23.
SchJMediumBullet

Attach to Form 990. SchJMediumBullet

See separate instructions.

OMB No. 1545-0047

2012

Open to Public Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC

Employer identification number

13-5644916

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed in Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes in line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain....

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all officers,
directors, trustees, and the CEO/Executive Director, regarding the items checked in line 1a? .......

Indicate which, if any, of the following the filing organization used to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed in Form 990, Part VII, Section A, line 1a with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? ................

Yes

Participate in, or receive payment from, a supplemental nonqualified retirement plan? .........

Participate in, or receive payment from, an equity-based compensation arrangement? .........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3) and 501(c)(4) organizations only must complete lines 5-9.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ...........................

Any related organization? .........................

If "Yes," to line 5a or 5b, describe in Part III.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ...........................

Any related organization? .........................

If "Yes," to line 6a or 6b, describe in Part III.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization provide any non-fixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Yes

Were any amounts reported in Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III .............................

If "Yes" to line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50053T

Schedule J (Form 990) 2012

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported in Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions, on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.
Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported as deferred in prior Form 990
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported as deferred in prior Form 990
(1)JOHN WALTERPRESIDENT & CEO	(i) (ii)	520,000	39,000	14,622	31,500	23,485	628,607
(2)JAMES T NANGLESVP & CFO	(i) (ii)	216,541	5,508	14,679	22,772	23,290	282,790
(3)LOUIS DEGENNAROCHIEF MISSION OFFICE	(i) (ii)	334,670	29,604	17,784	25,000	16,269	423,327
(4)RICHARD WINNEKERSVP RESEARCH	(i) (ii)	254,052	22,413	19,777	17,608	1,124	314,974
(5)GEORGE OMIROSCHIEF CAMPAIGN&FIELD	(i) (ii)	254,527	8,609	16,480	25,000	16,135	320,751
(6)KETING CHUVP RES THERAPY	(i) (ii)	227,038	6,152	39,829	4,018	13,740	290,777
(7)DAVID TIMKOSVP VOLUNTEER ENGAGE	(i) (ii)	235,178		17,672	24,085	16,106	293,041
(8)NANCY KLEINCHIEF MKTG & REVENUE	(i) (ii)	188,136		263,405	13,013	9,698	474,252

Schedule J (Form 990) 2012

Page 3

Part III

Supplemental Information

Complete this part to provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II.
Also complete this part for any additional information.

Identifier	Return Reference	Explanation
SEVERANCE, NONQUALIFIED, AND EQUITY-BASED PAYMENTS	SCHEDULE J, PAGE 1, PART I, LINE 4	NANCY KLEIN 254,754 0 0
NON-FIXED PAYMENTS PROVIDED	SCHEDULE J, PAGE 1, PART I, LINE 7	BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF GROSS REVENUE EXCEEDING BUDGTED GROSS REVENUE, EMPLOYEE INDIVIDUAL PERFORMANCE AND OTHER METRICS. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B) (II).

Schedule J (Form 990) 2012

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE M
(Form 990)

Department of the Treasury

Internal Revenue Service

Noncash Contributions

Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image

Attach to Form 990.

OMB No. 1545-0047

2012

Open to Public Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC

Employer identification number

13-5644916

Part I

Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..
5 Clothing and household goods .......
6 Cars and other vehicles ..
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .	X	102	1,094,571	MARKET VALUE
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...	X	56
20 Drugs and medical supplies .
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( PRINTED ITEMS )	X	9
26 Other ( FURNITURE&EQUIP )	X	2
27 Other ( VARIOUS )	X	90
28 Other ( )

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement ...

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1-28 that it

must hold for at least three years from the date of the initial contribution, and which is not required to be used

for exempt purposes for the entire holding period? ..................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any non-standard contributions?

Yes

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash

contributions? ..........................

32a

If "Yes," describe in Part II.

If the organization did not report an amount in column (c) for a type of property for which column (a) is checked,

describe in Part II.

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 51227J

Schedule M (Form 990) (2012)

Page 2

Part II

Supplemental Information. Complete this part to provide the information required by Part I, lines 30b,
32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

Identifier	Return Reference	Explanation
EXPLANATION FOR NOT REPORTING REVENUE	SCHEDULE M, PAGE 1, PART I, LINE 33	LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS.
SUPPLEMENTAL INFORMATION	SCHEDULE M, PAGE 2, PART II	PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS.

Schedule M (Form 990) (2012)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE O
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.

OMB No. 1545-0047

2012

Open to Public
Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC

Employer identification number

13-5644916

Identifier	Return Reference	Explanation
FIRST ACCOMPLISHMENT DESCRIPTION	FORM 990, PAGE 2, PART III, LINE 4A	CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2013, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 72 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2013, FOR THE SECOND YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN THREE OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - THE MALIGNANT STEM CELL IN AML AND MDS - NON-CUTANEOUS T-CELL LEUKEMIAS AND LYMPHOMAS - HIGH RISK MYELOMA CASES THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLICATIONS TO INCREASE THE LIKELIHOOD THAT NOVEL, POSSIBLY BREAKTHROUGH, TREATMENTS WILL BE AVAILABLE TO PATIENTS AS SOON AS POSSIBLE. THE PROGRAM INCLUDES: - THE ACADEMIC CONCIERGE DIVISION IDENTIFIES ESPECIALLY PROMISING LLS-FUNDED GRANT PROJECTS AND PROVIDES ADDITIONAL SUPPORT TO ADVANCE SELECTED PROJECTS TO THE PRODUCT STAGE. - THE BIOTECHNOLOGY ACCELERATOR DIVISION PARTNERS LLS WITH COMPANIES TO COMBINE SCIENTIFIC AND FINANCIAL RESOURCES AND ACCELERATE THE DEVELOPMENT OF POTENTIAL BLOOD CANCER THERAPIES THAT OTHERWISE MIGHT NOT BE PRIORITIZED BY THE COMPANY. - THE CLINICAL TRIALS DIVISION BRINGS CLINICAL TRIALS TO BLOOD CANCER PATIENTS IN THEIR COMMUNITIES, INCLUDING UNDER-REPRESENTED POPULATIONS, AND WITH THE ULTIMATE GOAL OF INCREASING PATIENT ENROLLMENT IN BLOOD CANCER TRIALS.
SECOND ACCOMPLISHMENT DESCRIPTION	FORM 990, PAGE 2, PART III, LINE 4B	WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH AND SPANISH. - 920,398 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2013 FINANCIAL ASSISTANCE IN 2013, A COMBINED 45,639,792 DOLLARS WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (2,989,442) AND CO-PAY ASSISTANCE PROGRAMS (42,650,350). PATIENT FINANCIAL AID PROGRAM FOR MORE THAN 46 YEARS, LLS HAS HELPED PATIENTS DEMONSTRATING SIGNIFICANT NEED TO OBTAIN FINANCIAL ASSISTANCE TO COVER A PORTION OF THEIR TREATMENT COSTS. THE LLS PATIENT FINANCIAL AID PROGRAM PROVIDES A LIMITED AMOUNT OF FINANCIAL ASSISTANCE TO HELP PATIENTS WITH SIGNIFICANT FINANCIAL NEED AND WHO ARE UNDER A DOCTOR'S CARE FOR A CONFIRMED BLOOD CANCER DIAGNOSIS. PATIENT FINANCIAL AID FUNDS ARE SUBJECT TO AVAILABILITY. - 29,894 PATIENTS RECEIVED FINANCIAL AID IN 2013 CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 18,259 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2013 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS.COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. - 34,809 PATIENT AND CAREGIVER PARTICIPANTS IN 2013 - 13,182 HEALTHCARE PROFESSIONAL PARTICIPANTS IN 2013 PROGRAMS FOR CHILDREN AND YOUNG ADULTS THE TRISH GREENE BACK TO SCHOOL PROGRAM FOR CHILDREN WITH CANCER FOCUSES ON INCREASING COMMUNICATION AMONG HEALTHCARE PROFESSIONALS, PARENTS, PATIENTS AND SCHOOL PERSONNEL TO SUPPORT CHILDREN, ADOLESCENTS AND YOUNG ADULTS LIVING WITH CANCER. PRINTED LITERATURE, VIDEOS AND OTHER MATERIALS TO AID THE PROCESS ARE AVAILABLE IN COMMUNITIES THROUGHOUT THE US AND CANADA VIA LLS CHAPTER OFFICES. THE PROGRAM INCLUDES STAYING CONNECTED: FACILITATING THE LEARNING EXPERIENCE DURING AND AFTER CANCER TREATMENT. THIS EDUCATION PROGRAM FOR SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS DESCRIBES PHYSICAL, COGNITIVE AND PSYCHOSOCIAL SHORT-AND LONG-TERM EFFECTS THAT CHILDREN, ADOLESCENTS AND YOUNG ADULTS MAY EXPERIENCE DURING AND AFTER TREATMENT. THE PROGRAM OFFERS GUIDANCE AND NUMEROUS RESOURCES TO HELP CHILDREN, ADOLESCENTS AND YOUNG ADULTS CONTINUE THEIR EDUCATION DURING AND AFTER TREATMENT. - 2,412 SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS PARTICIPATED IN THE 54 STAYING CONNECTED PROGRAMS ACROSS THE US AND CANADA IN 2013. FAMILY SUPPORT GROUPS LLS HAS DEVELOPED 415 FAMILY SUPPORT GROUPS AT CHAPTERS THROUGHOUT THE US AND CANADA. LLS ALSO HAS 843 VOLUNTEER SUPPORT GROUP FACILITATORS WITH BACKGROUNDS IN ONCOLOGY NURSING OR SOCIAL WORK. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. - 9,452 PARTICIPANTS IN FAMILY SUPPORT GROUPS IN 2013 PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 6,322 FIRST CONNECTIONS IN 2013
THIRD ACCOMPLISHMENT DESCRIPTION	FORM 990, PAGE 2, PART III, LINE 4C	OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 6 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 54,682 INQUIRIES IN 2013 THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, PATIENT FINANCIAL AID, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL-TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2013, 14 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS.
ALL OTHER ACCOMPLISHMENT DESCRIPTION	FORM 990, PAGE 2, PART III, LINE 4D	D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT.
FINANCIAL ACCOUNTS IN FOREIGN COUNTRIES	FORM 990, PART V, LINE 4B	CANADA
CLASSES OF MEMBERS OR STOCKHOLDERS	FORM 990, PAGE 6, PART VI, LINE 6	THE MEMBERS OF LLS CONSIST OF ONE ELECTED REPRESENTATIVE FROM EACH CHAPTER.
ELECTION OF MEMBERS AND THEIR RIGHTS	FORM 990, PAGE 6, PART VI, LINE 7A	THE BOARD OF REPRESENTATIVES (REPRESENTING THE CHAPTERS) ELECTS THE MEMBERS OF LLS'S GOVERNING BODY, ITS NATIONAL BOARD OF DIRECTORS.
DECISIONS SUBJECT TO APPROVAL OF MEMBERS	FORM 990, PAGE 6, PART VI, LINE 7B	SIGNIFICANT DECISIONS AFFECTING THE CHAPTERS REQUIRE AN APPROVING VOTE BY THE CHAPTER DELEGATES. DECISIONS NOT SIGNIFICANTLY AFFECTING THE CHAPTERS DO NOT REQUIRE APPROVAL FROM THE CHAPTER DELEGATES.
ORGANIZATION'S PROCESS USED TO REVIEW FORM 990	FORM 990, PAGE 6, PART VI, LINE 11B	THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CAO & CFO, SR. VICE PRESIDENT OF FINANCE, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990 WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING BY POSTING THE FORM ON AN INTRANET WEBSITE.
ENFORCEMENT OF CONFLICTS POLICY	FORM 990, PAGE 6, PART VI, LINE 12C	ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE.
COMPENSATION PROCESS FOR TOP OFFICIAL	FORM 990, PAGE 6, PART VI, LINE 15A	THE EXECUTIVE COMMITTEE, COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, REVIEWS AND MONITORS THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THE COMMITTEE OBTAINED A SURVEY OF OTHER NOT-FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE REVIEW WAS DOCUMENTED IN THE EXECUTIVE COMMITTEE'S MINUTES.
COMPENSATION PROCESS FOR OFFICERS	FORM 990, PAGE 6, PART VI, LINE 15B	THE EXECUTIVE COMMITTEE, COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS, REVIEWED A SURVEY OF OTHER NOT-FOR-PROFIT ORGANIZATIONS' COMPENSATION RANGES AND COMPARED THIS TO THE OTHER OFFICER'S SALARY AND DETERMINED THAT IT WAS APPROPRIATE. THE REVIEW WAS DOCUMENTED IN THE EXECUTIVE COMMITTEE'S MINUTES.
STATES WHERE COPY OF RETURN IS FILED	FORM 990, PAGE 6, PART VI, LINE 17	ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA
GOVERNING DOCUMENTS DISCLOSURE EXPLANATION	FORM 990, PAGE 6, PART VI, LINE 19	THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE, WHEN CHANGES ARE MADE, AS PART OF THE 990 AVAILABLE FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990.
GROUP RETURN METHOD	FORM 990, PAGE 7, PART VII	PARENT ORGANIZATION HAS FILED A CONSOLIDATED RETURN
RECONCILIATION OF CHANGES - OTHER	FORM 990, PART XI, LINE 9	LLS CANADA REVENUE 13,446,524 ROUNDING -305 LSRP CONTRIBUTION -681,316 LLS CANADA EXPENSES -13,101,520 FOREIGN CURRENCY TRANSALATION ADJUSTMENT -83,698 ROUNDING -1,506
OTHER CHANGES IN NET ASSETS EXPLANATION	FORM 990, PART XI, LINE 9	CHANGE IN NET ASSETS LLS CANADA -345,004 LSRP CONNTRIBUTION 681,316 FINANCIAL STATEMENT ROUNDING 102

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990 or 990-EZ) 2012

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE R
(Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" to Form 990, Part IV, line 33, 34, 35, 36, or 37.
MediumBullet

Attach to Form 990. MediumBullet

See separate instructions.

OMB No. 1545-0047

2012

Open to Public Inspection

Name of the organization

THE LEUKEMIA & LYMPHOMA SOCIETYINC

Employer identification number

13-5644916

Part I

Identification of Disregarded Entities (Complete if the organization answered "Yes" to Form 990, Part IV, line 33.)

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity

Part II

Identification of Related Tax-Exempt Organizations (Complete if the organization answered "Yes" to Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	Yes	No
(1) THE LLS OF CANADA 804 2 LANSING SQUARE TORONTO M2J4P8 CA	PART VII	CA			NA		No
(2) THE LLS RESEARCH PROGRAMS INC 1311 MAMARONECK AVENUE WHITE PLAINS,NY10605 13-3470494	PART VII	DE	501C3	11B	LLS INC	Yes
(3) THE LLS RESEARCH FOUNDATION 1311 MAMARONECK AVENUE WHITE PLAINS,NY10605 13-3709252	PART VII	DE	501C3	11B	LLS INC	Yes

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50135Y

Schedule R (Form 990) 2012

Page 2

Part III

Identification of Related Organizations Taxable as a Partnership (Complete if the organization answered "Yes" to Form 990, Part IV, line 34 because it had one or more related organizations treated as a partnership during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Part IV

Identification of Related Organizations Taxable as a Corporation or Trust (Complete if the organization answered "Yes" to Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(i) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	Yes	No

Schedule R (Form 990) 2012

Page 3

Part V

Transactions With Related Organizations (Complete if the organization answered "Yes" to Form 990, Part IV, line 34, 35b, or 36.)

Note. Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

Yes

1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

a Receipt of (i) interest (ii) annuities (iii) royalties or (iv) rent from a controlled entity . . . . . . . . . . . . . . . . . . . . . . .

b Gift, grant, or capital contribution to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

c Gift, grant, or capital contribution from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

d Loans or loan guarantees to or for related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

e Loans or loan guarantees by related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

f Dividends from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

g Sale of assets to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

h Purchase of assets from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

i Exchange of assets with related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

j Lease of facilities, equipment, or other assets to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . .

k Lease of facilities, equipment, or other assets from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . .

l Performance of services or membership or fundraising solicitations for related organization(s) . . . . . . . . . . . . . . . . . . . .

m Performance of services or membership or fundraising solicitations by related organization(s) . . . . . . . . . . . . . . . . . . . .

n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s) . . . . . . . . . . . . . . . . . . . . .

Yes

o Sharing of paid employees with related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

p Reimbursement paid to related organization(s) for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

q Reimbursement paid by related organization(s) for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

r Other transfer of cash or property to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

s Other transfer of cash or property from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of other organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved
(1) THE LEUKEMIA & LYMPHOMA SOCIETY	D	146,528	COST
(2) OF CANADA
(3) THE LLS RESEARCH PROGRAMS INC	C	681,316	COST

Schedule R (Form 990) 2012

Page 4

Part VI

Unrelated Organizations Taxable as a Partnership (Complete if the organization answered "Yes" to Form 990, Part IV, line 37.)

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(e) Are all partners section 501(c)(3) organizations?		(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?
(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	Yes	No	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Schedule R (Form 990) 2012

Page 5

Part VII

Supplemental Information

Complete this part to provide additional information for responses to questions on Schedule R (see instructions).

Identifier	Return Reference	Explanation
GROUP EXEMPTION RELATIONSHIPS	SCHEDULE R	THE LEUKEMIA LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA LYMPHOMA SOCIETY INC IN CANADA THE LEUKEMIA SOCIETY RESEARCH PROGRAMS INC AND THE LEUKEMIA RESEARCH FOUNDATION INC SUPPORT THE ACTIVITIES OF THE LEUKEMIA LYMPHOMA SOCIETY INC

Additional Data

Software ID:
Software Version:

1	Briefly describe the organization’s mission or most significant activities: OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ........	3	22
4	Number of independent voting members of the governing body (Part VI, line 1b) .....	4	22
5	Total number of individuals employed in calendar year 2011 (Part V, line 2a) ......	5	1,580
6	Total number of volunteers (estimate if necessary) .............	6	3,000,000
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ........	7a	0
b	Net unrelated business taxable income from Form 990-T, line 34 .........	7b

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	282,672,073	279,789,665
9	Program service revenue (Part VIII, line 2g) .........		0
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	8,039,879	8,133,222
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	2,111,041	2,435,580
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)...................	292,822,993	290,358,467
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	115,731,627	117,726,007
14	Benefits paid to or for members (Part IX, column (A), line 4).....		0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	86,776,477	90,034,581
16a	Professional fundraising fees (Part IX, column (A), line 11e).....	10,175,403	10,134,488
b	Total fundraising expenses (Part IX, column (D), line 25) 48,057,833
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e)....	79,711,007	89,083,589
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	292,394,514	306,978,665
19	Revenue less expenses. Subtract line 18 from line 12.......	428,479	-16,620,198
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16).............	223,445,924	236,325,556
21	Total liabilities (Part X, line 26).............	109,397,145	135,316,123
22	Net assets or fund balances. Subtract line 21 from line 20.....	114,048,779	101,009,433

Sign Here

	Signature of officer	Date

	Type or print name and title


4a	(Code: ) (Expenses $ 76,025,725 including grants of $ 72,086,215 ) (Revenue $ )
	A) RESEARCH PROGRAMS: WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVED OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. (CONTINUED ON SCHEDULE O) TO DATE, LLS HAS INVESTED ALMOST 1 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2013, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 72 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2013, FOR THE SECOND YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN THREE OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - THE MALIGNANT STEM CELL IN AML AND MDS - NON-CUTANEOUS T-CELL LEUKEMIAS AND LYMPHOMAS - HIGH RISK MYELOMA CASES THE THERAPY ACCELERATION PROGRAM THIS STRATEGIC INITIATIVE WAS LAUNCHED IN 2007 TO MOVE NEW TREATMENTS AND DIAGNOSTICS THROUGH PRECLINICAL DEVELOPMENT AND CLINICAL TRIALS, FASTER. USING MILESTONE-DRIVEN CONTRACTS AND WORKING IN CONCERT WITH ACADEMIC INVESTIGATORS, MEDICAL CENTERS AND COMPANIES, LLS IS FURTHER BRIDGING THE GAP BETWEEN DISCOVERY AND HUMAN APPLICATIONS TO INCREASE THE LIKELIHOOD THAT NOVEL, POSSIBLY BREAKTHROUGH, TREATMENTS WILL BE AVAILABLE TO PATIENTS AS SOON AS POSSIBLE. THE PROGRAM INCLUDES: - THE ACADEMIC CONCIERGE DIVISION IDENTIFIES ESPECIALLY PROMISING LLS-FUNDED GRANT PROJECTS AND PROVIDES ADDITIONAL SUPPORT TO ADVANCE SELECTED PROJECTS TO THE PRODUCT STAGE. - THE BIOTECHNOLOGY ACCELERATOR DIVISION PARTNERS LLS WITH COMPANIES TO COMBINE SCIENTIFIC AND FINANCIAL RESOURCES AND ACCELERATE THE DEVELOPMENT OF POTENTIAL BLOOD CANCER THERAPIES THAT OTHERWISE MIGHT NOT BE PRIORITIZED BY THE COMPANY. - THE CLINICAL TRIALS DIVISION BRINGS CLINICAL TRIALS TO BLOOD CANCER PATIENTS IN THEIR COMMUNITIES, INCLUDING UNDER-REPRESENTED POPULATIONS, AND WITH THE ULTIMATE GOAL OF INCREASING PATIENT ENROLLMENT IN BLOOD CANCER TRIALS.

4b	(Code: ) (Expenses $ 107,397,528 including grants of $ 45,639,792 ) (Revenue $ )
	B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1,129,813 PEOPLE ACROSS THE UNITED STATES (US) CURRENTLY BATTLE LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS A FREE, COMPREHENSIVE ARRAY OF SERVICES TO BLOOD CANCER PATIENTS AND THEIR FAMILIES, VOLUNTEER CAREGIVERS AND ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. (CONTINUED ON SCHEDULE O) LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL; AND CURRENT AND ACCURATE INFORMATION ABOUT SYMPTOMS, RISK FACTORS AND TREATMENT. PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS THROUGH THE INFORMATION RESOURCE CENTER AND LLS CHAPTERS. MANY MATERIALS ARE ALSO AVAILABLE TO VIEW AND DOWNLOAD AT WWW.LLS.ORG/RESOURCECENTER. DOWNLOADABLE MATERIALS ARE AVAILABLE IN ENGLISH AND SPANISH. - 920,398 PRINTED BOOKLETS, BROCHURES, FACT SHEETS, EDUCATION PROGRAM TRANSCRIPTS AND DVDS DISTRIBUTED IN 2013 FINANCIAL ASSISTANCE IN 2013, A COMBINED 45,639,792 DOLLARS WAS DISBURSED TO PATIENTS THROUGH THE LLS PATIENT FINANCIAL AID (2,989,442) AND CO-PAY ASSISTANCE PROGRAMS (42,650,350). PATIENT FINANCIAL AID PROGRAM FOR MORE THAN 46 YEARS, LLS HAS HELPED PATIENTS DEMONSTRATING SIGNIFICANT NEED TO OBTAIN FINANCIAL ASSISTANCE TO COVER A PORTION OF THEIR TREATMENT COSTS. THE LLS PATIENT FINANCIAL AID PROGRAM PROVIDES A LIMITED AMOUNT OF FINANCIAL ASSISTANCE TO HELP PATIENTS WITH SIGNIFICANT FINANCIAL NEED AND WHO ARE UNDER A DOCTOR'S CARE FOR A CONFIRMED BLOOD CANCER DIAGNOSIS. PATIENT FINANCIAL AID FUNDS ARE SUBJECT TO AVAILABILITY. - 29,894 PATIENTS RECEIVED FINANCIAL AID IN 2013 CO-PAY ASSISTANCE PROGRAM THIS CO-PAY ASSISTANCE PROGRAM HELPS PATIENTS WITH MANY KINDS OF BLOOD CANCERS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO-PAYMENT OBLIGATIONS RELATED TO TREATING THEIR CANCER. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUND AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. FOR MORE INFORMATION CALL, (877) LLS-COPAY (877) 557-2672 OR VISIT WWW.LLS.ORG/COPAY. - 18,259 PATIENTS RECEIVED LLS CO-PAY ASSISTANCE IN 2013 COMMUNITY PROGRAMS EACH LLS CHAPTER OFFICE IS STAFFED WITH A PATIENT SERVICES MANAGER (PSM) WHO OVERSEES SERVICES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PSMS ARE HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING OR SOCIAL WORK. PSMS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS.COMMUNITY-BASED EDUCATION AND OUTREACH, SUPPORT AND PUBLIC POLICY AND ADVOCACY PROGRAMS ARE AVAILABLE. - 34,809 PATIENT AND CAREGIVER PARTICIPANTS IN 2013 - 13,182 HEALTHCARE PROFESSIONAL PARTICIPANTS IN 2013 PROGRAMS FOR CHILDREN AND YOUNG ADULTS THE TRISH GREENE BACK TO SCHOOL PROGRAM FOR CHILDREN WITH CANCER FOCUSES ON INCREASING COMMUNICATION AMONG HEALTHCARE PROFESSIONALS, PARENTS, PATIENTS AND SCHOOL PERSONNEL TO SUPPORT CHILDREN, ADOLESCENTS AND YOUNG ADULTS LIVING WITH CANCER. PRINTED LITERATURE, VIDEOS AND OTHER MATERIALS TO AID THE PROCESS ARE AVAILABLE IN COMMUNITIES THROUGHOUT THE US AND CANADA VIA LLS CHAPTER OFFICES. THE PROGRAM INCLUDES STAYING CONNECTED: FACILITATING THE LEARNING EXPERIENCE DURING AND AFTER CANCER TREATMENT. THIS EDUCATION PROGRAM FOR SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS DESCRIBES PHYSICAL, COGNITIVE AND PSYCHOSOCIAL SHORT-AND LONG-TERM EFFECTS THAT CHILDREN, ADOLESCENTS AND YOUNG ADULTS MAY EXPERIENCE DURING AND AFTER TREATMENT. THE PROGRAM OFFERS GUIDANCE AND NUMEROUS RESOURCES TO HELP CHILDREN, ADOLESCENTS AND YOUNG ADULTS CONTINUE THEIR EDUCATION DURING AND AFTER TREATMENT. - 2,412 SCHOOL PERSONNEL, HEALTHCARE PROFESSIONALS AND PARENTS PARTICIPATED IN THE 54 STAYING CONNECTED PROGRAMS ACROSS THE US AND CANADA IN 2013. FAMILY SUPPORT GROUPS LLS HAS DEVELOPED 415 FAMILY SUPPORT GROUPS AT CHAPTERS THROUGHOUT THE US AND CANADA. LLS ALSO HAS 843 VOLUNTEER SUPPORT GROUP FACILITATORS WITH BACKGROUNDS IN ONCOLOGY NURSING OR SOCIAL WORK. GROUPS ARE GUIDED BY TWO VOLUNTEER ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. - 9,452 PARTICIPANTS IN FAMILY SUPPORT GROUPS IN 2013 PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT-VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE NEW PATIENT TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS. - 6,322 FIRST CONNECTIONS IN 2013

4c	(Code: ) (Expenses $ 41,981,280 including grants of $ ) (Revenue $ )
	C) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION INFORMATION RESOURCE CENTER PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. (CONTINUED ON SCHEDULE O) LLS INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. LLS INFORMATION SPECIALISTS CONDUCT CLINICAL-TRIAL SEARCHES TO HELP PATIENTS WORK WITH THEIR DOCTORS TO FIND OUT ABOUT SPECIFIC CLINICAL TRIALS. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 6 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. - 54,682 INQUIRIES IN 2013 THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING CO-PAY ASSISTANCE, PATIENT FINANCIAL AID, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH, AND CLINICAL-TRIAL SEARCHES VIA AN ONLINE CLINICAL-TRIAL SEARCH SERVICE THAT OFFERS PATIENTS AND CAREGIVERS IMMEDIATE ACCESS TO LISTINGS OF BLOOD CANCER CLINICAL TRIALS. PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS CAN INTERACT WITH LLS AND ONE ANOTHER THROUGH SOCIAL NETWORKING, PODCASTS AND ENEWSLETTERS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS SPONSORS TELEPHONE AND WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES. IN 2013, 14 LLS NATIONAL EDUCATION PROGRAMS FEATURED DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT TREATMENT OPTIONS FROM WORLD RENOWNED CLINICAL EXPERTS. OPPORTUNITIES ARE PROVIDED TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. THESE PROGRAMS OFFER CONTINUING EDUCATION CREDITS FOR NURSES AND SOCIAL WORKERS. LLS ALSO SPONSORS A RANGE OF PROFESSIONAL EDUCATION PROGRAMS. RECENT PROGRAMS EXPLORED THE ADMINISTRATION AND MANAGEMENT OF CURRENT THERAPIES FOR HEMATOLOGIC MALIGNANCIES AND COMMUNICATION AMONG PRIMARY CARE PROVIDERS AND HEMATOLOGISTS/ONCOLOGISTS IN MANAGING PATIENTS WITH HEMATOLOGIC CANCER. UPCOMING PROGRAMS ARE POSTED AT WWW.LLS.ORG/PROGRAMS AND ARCHIVES OF PAST PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PASTPROGRAMS. PROFESSIONAL EDUCATION PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/PROFESSIONALED. LLS ALSO OFFERS DISEASE-SPECIFIC WEBCASTS PRESENTED BY WORLD RENOWNED CLINICAL EXPERTS. THESE CAN BE ACCESSED AT WWW.LLS.ORG/WEBCASTS.

	(Code: ) (Expenses $ 9,062,232 including grants of $ ) (Revenue $ )
	D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT.

4d	Other program services (Describe in Schedule O.)
	(Expenses $ 9,062,232 including grants of $ ) (Revenue $ )
4e	Total program service expenses234,466,765

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)............	2,745,676	282,843

				(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512, 513, or 514
1a	Federated campaigns..1a		2,264,122
b	Membership dues....1b
c	Fundraising events....1c		161,261,897
d	Related organizations...1d		681,316
e	Government grants (contributions)1e

f	All other contributions, gifts, grants, and similar amounts not included above1f		115,582,330

g	Noncash contributions included in lines 1a-1f:$		1,094,571
h	Total. Add lines 1a-1f.......			279,789,665
			Business Code
2a
b
c
d
e
f	All other program service revenue .
g	Total. Add lines 2a–2f........
3	Investment income (including dividends, interest, and other similar amounts).......			2,256,195			2,256,195
4	Income from investment of tax-exempt bond proceeds..
5	Royalties...........			4,441			4,441
		(i) Real	(ii) Personal
6a	Gross rents
b	Less: rental expenses
c	Rental income or (loss)
d	Net rental income or (loss).......
		(i) Securities	(ii) Other
7a	Gross amount from sales of assets other than inventory	57,803,147
b	Less: cost or other basis and sales expenses	51,926,120
c	Gain or (loss)	5,877,027
d	Net gain or (loss)..........			5,877,027			5,877,027
8a	Gross income from fundraising events (not including $ 161,261,897 of contributions reported on line 1c). See Part IV, line 18 ..
	a		33,429,268
b	Less: direct expenses ...b		33,429,268
c	Net income or (loss) from fundraising events..
9a	Gross income from gaming activities. See Part IV, line 19 ...
	a		778,030
b	Less: direct expenses ...b		321,117
c	Net income or (loss) from gaming activities...			456,913	456,913
10a	Gross sales of inventory, less returns and allowances .
	a
b	Less: cost of goods sold ..b
c	Net income or (loss) from sales of inventory..
Miscellaneous Revenue			Business Code
11a	GRANT TERMINATION		541900	1,844,147			1,844,147
b	OTHER MISCELLANEOUS		900099	130,079			130,079
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......			1,974,226
12	Total revenue. See Instructions......			290,358,467	456,913		10,111,889


				(A) Beginning of year		(B) End of year
1	Cashnon-interest-bearing .............			6,532,613	1	5,620,937
2	Savings and temporary cash investments .........			17,034,917	2	19,656,020
3	Pledges and grants receivable, net ...........			5,178,782	3	7,252,079
4	Accounts receivable, net .............			264,507	4	81,719
5	Loans and other receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of Schedule L ..................
					5
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), persons described in section 4958(c)(3)(B), and contributing employers and sponsoring organizations of section 501(c)(9) voluntary employees' beneficiary organizations (see instructions) Complete Part II of Schedule L
					6
7	Notes and loans receivable, net .............				7
8	Inventories for sale or use ..............				8
9	Prepaid expenses and deferred charges ..........			5,875,009	9	4,851,345
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	21,600,484
b	Less: accumulated depreciation .....	10b	11,006,325	6,641,060	10c	10,594,159
11	Investments—publicly traded securities ..........			138,026,930	11	112,406,398
12	Investments—other securities. See Part IV, line 11 .....			43,892,106	12	75,862,899
13	Investments—program-related. See Part IV, line 11 .....				13
14	Intangible assets ...............				14
15	Other assets. See Part IV, line 11 ...........				15
16	Total assets. Add lines 1 through 15 (must equal line 34)......			223,445,924	16	236,325,556
17	Accounts payable and accrued expenses .........			19,660,610	17	20,652,928
18	Grants payable .................			72,815,341	18	80,460,957
19	Deferred revenue ................			16,921,194	19	34,202,238
20	Tax-exempt bond liabilities .............				20
21	Escrow or custodial account liability. Complete Part IV of Schedule D..				21
22	Loans and other payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
	persons. Complete Part II of Schedule L..........				22
23	Secured mortgages and notes payable to unrelated third parties ..				23
24	Unsecured notes and loans payable to unrelated third parties ....				24
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D....................				25
26	Total liabilities. Add lines 17 through 25.........			109,397,145	26	135,316,123
	Organizations that follow SFAS 117 (ASC 958), check here and complete lines 27 through 29, and lines 33 and 34.
27	Unrestricted net assets ..............			100,978,174	27	90,324,737
28	Temporarily restricted net assets ...........			10,221,074	28	7,775,266
29	Permanently restricted net assets ...........			2,849,531	29	2,909,430
	Organizations that do not follow SFAS 117 (ASC 958), check here and complete lines 30 through 34.
30	Capital stock or trust principal, or current funds ........				30
31	Paid-in or capital surplus, or land, building or equipment fund .....				31
32	Retained earnings, endowment, accumulated income, or other funds				32
33	Total net assets or fund balances ...........			114,048,779	33	101,009,433
34	Total liabilities and net assets/fund balances ........			223,445,924	34	236,325,556

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If “Yes,”the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926)......................................	Yes	No
2	Did the organization have an interest in a foreign trust during the tax year? If “Yes,” the organizationmay be required to file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A).......................................	Yes	No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471)..............................	Yes	No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If "Yes," the organization may be required to file Form 8621, Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621)	Yes	No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships. (see Instructions for Form 8865)....................................	Yes	No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to file Form 5713, International Boycott Report (see Instructions for Form 5713)................................................	Yes	No